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ABSTRACT
Arginine Vasopressin (AVP) is also known as the anti-diuretic hormone
(ADH). The two regulatory effects that provided these names (increasing blood
pressure by causing vasoconstriction, and reducing water loss by promoting water re-
absorption in the kidney) are commonly described as the only physiologically
relevant functions of this peptide. However, other cellular effects of AVP have also
been described both in vitro and in vivo. For example, in the adult mammal, AVP has
been shown to play a role in platelet aggregation, hepatic glycogenolysis, and
memory consolidation.
Studies described in this thesis set out to examine a potential additional
function for AVP. Data were published suggesting there is a significant amount of
AVP immunoreactivity (AVP-ir) in foetal human skeletal muscle. AVP-ir was
described at concentrations significantly higher than circulating levels of AVP, and
was shown to decrease with increased gestation age. Also, in rat myogenic cell lines,
incubation with AVP resulted in promotion of fusion and up-regulation of muscle
specific gene expression. This effect was described as being mediated by the Via
vasopressin receptor. Taken together, these results suggest a role for vasopressin in
skeletal muscle development and point to an additional alternative site for the
synthesis of biologically active AVP. An extraction method was developed using
solid phase extraction (SPE) followed by radioimmunoassay. The physical recovery
of the SPE step was reproducibly better than 70% when extracting AVP from
homogenised muscle tissues. The radioimmunoassay had a cross reactivity of less
than 0.01% with both oxytocin and arginine vasotocin. This extraction method was
developed in response to the demonstration that the direct assay of acidified extracts
could not provide an accurate measurement of AVP in extracted muscle. It was
demonstrated that acid present in the samples will interfere with the assay, and it is
argued that this artefact probably gave rise to the AVP-ir reported previously.
AVP-ir in foetal muscle samples using SPE was not significant. This was in
contrast to levels found in positive control tissues - foetal human adrenal and
pituitary glands and adult rat adrenal glands - where AVP-ir levels were in
agreement with previously published data. A relationship between the age of the
foetus and the vasopressin contained in the adrenal gland was observed. Rat adrenal
gland contained significant amounts of AVP-ir, and when immunohistochemistry
was used to confirm these findings, regional distribution ofAVP-ir in the rat adrenal
medulla tissue was observed. In Western blot analysis of extract of foetal muscle,
bands were seen at appropriate molecular weights using a specific antibody to the
Via receptor.
Concentrations of AVP required in vitro to cause fusion of muscle cells and
concomitant expression of relevant muscle specific genes could not be demonstrated
in any sampled human foetal muscle. Evidence exists that there is a role for AVP in
the regulation of carbohydrate metabolism in skeletal muscle, thus explaining the
presence of the receptors without the need for participation in the process of muscle
development. On this basis, it is concluded that it is unlikely that vasopressin is
involved in the development of skeletal muscle in the human foetus. The discovery
of a regional distribution of AVP-ir in the rat adrenal gland merits further
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Arginine-8-vasopressin (AVP - also referred to as vasopressin) is also known
as the anti-diuretic hormone (ADH). Study of this peptide has proceeded for almost a
hundred years largely on the basis that vasopressin has an exclusive source and a
defined set of targets. That is, it is synthesised in the cell bodies of magnocellular
neurones grouped together in a number of tracts of the anterior hypothalamus,
transported along their axons to be stored in, and secreted from, the nerve endings
that reside in the posterior pituitary gland. Once secreted into the blood stream, the
peptide hormone circulates either to the kidneys where it exerts an anti-diuretic
effect, or acts on smooth muscle cells in blood vessels, resulting in a vasopressor
effect. These actions of vasopressin were first described and demonstrated in
remarkable experiments either using whole organ preparations or whole animal
studies and the two names subsequently arose from the two roles designated as the
primary functions of this peptide. Since those initial demonstrations, the
investigation of vasopressin has passed from a descriptive, systemic phase to a phase
based on molecular investigations, in which the mechanism of expression and
secretion of the peptide and the cellular basis of its actions have been elucidated.
But the advent of more sensitive and sophisticated methods of investigation
has also shown that a restricted dual role for vasopressin is not a complete account of
its functions. Arginine vasopressin is found exclusively in mammals, but it is a
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member of a family of peptides with remarkably similar structures, known
collectively as the neurohypophyseal (NHP) hormones. Vasopressin-like peptides
have been detected in many species, and can be used to trace phylogenetic trees
through structural changes in the molecule seen in different vertebrate groups.
Vasopressin has been shown to act on many tissue types. Heller, in a review
covering early neurohypophyseal research, states,
"...it might be said that there is no endocrine organ whose active products
exert so many different actions." (1).
Even when this point of view was published much of the data on which this
thesis is founded were not available. Since the initial descriptions of the influences of
vasopressin on kidney tubules and blood vessels, vasopressin receptors and the
effects of vasopressin have been described in the mammal at the cellular level in
many different tissues - a list would include blood platelets, cerebral cortex, thymus,
lateral spinal column, heart, lung, spleen, uterus, breast, liver, testis, pancreas,
gastrointestinal tract and the adrenal gland. In addition, vasopressin has been shown
to have a role in complex social behaviour and to enhance memory consolidation.
This multi-functional aspect of vasopressin in different physiological systems raises
the question of the possibility of an 'original' function, and an 'original' ancestral
peptide. Vasopressin now has three recognised receptors; they are all members of the
same super family of G-protein coupled receptors. As a starting point it seems logical
to suggest that a single progenitor peptide existed, with a single cognate receptor and
a single function. Subsequently a journey of mutation, with addition and/or change of
function, has occurred until we arrive at the present situation, where vasopressin and
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all the related peptides are involved in many different, discrete systems. This
evolutionary process is a subject for much speculation.
It is also apparent that the hypothalamic magnocellular neurone is not the
only site of vasopressin synthesis. Parvocellular neurones of the hypothalamus and
cells in other tissues of both the brain and the periphery have been shown to fulfil a
set of criteria that suggest that these cells are capable of the synthesis of biologically
active vasopressin.
With this in mind, vasopressin, it can be argued, fulfils much more than an
endocrine role. In other systems or tissues, it could be serving a paracrine or
autocrine role. With such a wide range of effects, and with the differences in function
between species and questions of physiological relevance in some species, it is
almost impossible to present a complete and fully integrated description of
vasopressin and its functions. But certain specific examples exist that lend
themselves to a more detailed analysis and it would seem that a viable way to
consider tissues involved is to distinguish between those tissues that only possess
vasopressin receptors, and those tissues that apparently have the ability to synthesise
biologically active vasopressin as well as functional receptors. Tissues that only
express the receptors are under the 'control' of blood vasopressin levels, and so
would conform to a consistent pattern of response within the physiological context of
a rise (or drop) in these vasopressin levels. But those tissues that can produce a much
higher local concentration can be considered as functioning within a closed system
with little influence from or on the hypothalamo-neurohypophyseal system, albeit in
co-operation with other regulators. In particular the adrenal gland has been the most
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extensively studied example of this, and serves as a model for the examination of
other putative sites of peripheral vasopressin synthesis and local action.
The participation of vasopressin in such closed systems should be considered
as an important physiological aspect of function, because this peptide (along with
others) can be considered to have evolved to the point where it is now integrally
involved in many related processes. An intriguing aspect of this is the observation
that vasopressin has been implicated as a growth factor in certain types of cancer.
This effect could be considered as co-option of a normal physiological function - the
vasopressin gene's participation in the growth of tumours should perhaps be viewed
as a corruption of existing processes rather than a novel mechanism in itself.
A potential new role for vasopressin is discussed, that of a factor in the
development of differentiated muscle tissue in the foetus. High levels of apparently
specific vasopressin immunoreactivity (AVP-ir) have been described in samples of
human foetal muscle, and work performed using rat myoblast cell lines suggest a
physiological function for arginine vasopressin in the process of muscle development
1.2 Early neurohypophyseal hormone research
Looking at the literature on the study of vasopressin and oxytocin (OT), one
is struck by the way the emergence of information about the peptide has mirrored the
progression of technology, and the use of more sophisticated and sensitive
techniques in science. The neurohypophyseal hormones have been the longest and
most studied biological peptides, and their biological actions, structure and sources
were the first examples of the description of such characteristics. Where vasopressin
and oxytocin have led, so other peptide hormones have followed.
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The first phase of the progression is the description of the systemic effects of
vasopressin and oxytocin, culminating in the chemical synthesis of vasopressin.
Oxytocin was the first peptide hormone to be synthesised in vitro, and vasopressin
was synthesised soon afterwards (2, 3). This period of time is fascinating, as journal
articles track the gradual gathering of information. Several reviews have been
published about early neurohypophyseal peptide research, and much of the
information presented here is drawn from these reviews.
After the report of the first synthesis of the peptide, there is a movement into
the 'molecular' phase of study. This phase leads up to the present, and the knowledge
we have about the processes involved in the transcription, translation, maturation,
storage and secretion of vasopressin in the hypothalamo-neurohypophyseal system.
Clearly, there is an unequal division of information in these two phases, and so the
second phase of study is presented as a review of the information we have now,
rather than a review of the steps in discovery from the synthesis of vasopressin to the
time ofwriting.
The study of vasopressin started with the recognition in the eighteenth
century by the Venetian anatomist Santorini that the anterior pituitary gland was not
connected to the pituitary stalk (4). After this distinction between the 'pars anterior'
and 'pars posterior', Soemmering (in 1778) proposed an alternative to these names -
the hypophysis - and the term neurohypophysis was born. Following this addition to
the nomenclature, little progress (in the form of published reports) was made for over
a century, something Heller tentatively explains by saying
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"...when studied with ordinary methods of fixation and staining, the posterior lobe
has a rather nondescript appearance." (4).
But study of the pharmacology and physiology of vasopressin started with the
publication of a communication by Oliver and Schafer in 1895 (5). This study
reported that extracts of fresh whole pituitary gave rise to an elevation of blood
pressure when injected into anaesthetised mammals. Three years later, Howell
confirmed that the vasopressor-causing principle was in the posterior pituitary by
showing that anterior pituitary extracts had little or no effect on blood pressure (6).
Schafer and his colleagues observed diuresis and expansion of the kidney during and
after their experiments, and for many years the consensus opinion was that
neurohypophyseal extracts were actually diuretic. That the reverse was true (in
situations where the animals urine did not have a higher osmotic pressure than
plasma) was demonstrated simultaneously by "two venturesome clinicians" (7), Von
den Velden and Farini. Both of these investigators showed that injecting extracts of
posterior pituitary glands into patients secreting large volumes ofweak urine reduced
this diuresis (8, 9). Von den Velden took initial observations one step further and
showed that the extract also reduced water diuresis in healthy subjects, establishing
that the active principle had an effect in the normal physiological state. This
observation was repeated by others, and was also shown to occur in a similarly
treated rabbit.
Demonstration of the effect of anti-diuresis by posterior pituitary extract was
followed by a description of the mechanism of anti-diuresis, by Starling and Verney.
They isolated a kidney in a "heart lung" perfusion circuit - it produced dilute urine.
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Extract from the posterior pituitary reduced the amount of urine and increased the
concentration of the urine produced. Further, when a head was included in the circuit
a similar effect was seen. When the neurohypophysis was removed from the head
prior to the set up of the circuit, anti-diuresis was not observed (7). This was the most
rigorous proof thus far that the active anti-diuretic principle came from the posterior
pituitary, albeit on the understanding that these experiments have probably never
been repeated by anyone else (7). Later, Verney showed that the anti-diuretic effect
could be elicited by causing a small rise in plasma osmotic pressure using hypertonic
saline (4, 7).
Bargmann used staining of the structure of the hypothalamus and posterior
pituitary to persuade a sceptical mammalian endocrinologists that neurohypophyseal
hormones were produced in the hypothalamus (10).
Four biological actions ascribed to posterior pituitary extracts were
eventually established - uterus contraction (an oxytocic action), milk ejection (a
galactagogic action), increase of blood pressure (a vasopressor action) and renal
urine/water reabsorption (an anti-diuretic action). But the nature of the source of
these activities was still not clear. Abel and co-workers postulated a "mother
molecule", in which all four effects were observed to be exerted by the same protein,
whereas Dudley was equally convinced of the existence of distinct principles (11).
Van Dyke described the isolation of a protein of molecular weight 30,000 Dalton
(Da) that possessed all four activities, whereas Du Vignead showed that two small
peptides could be isolated which split the activities. Despite the fact that Du Vignead
had determined the structure of vasopressin and synthesised it along with oxytocin, it
was still not clear which of the two possibilities was the genuine physiological state
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and which was produced as experimental artefact. Chauvet and colleagues showed
that the Van Dyke protein could be dissociated into a heavier inactive portion and the
smaller active portion. Moreover, the two could be re-complexed in a stoichiometric
mixture in the right conditions (12). The term neurophysin was suggested for the
inactive protein element, which was later shown to contain two homologous
components that could be distinguished by their N-terminal sequences (13). The Van
Dyke complex was prepared from posterior pituitary glands from a variety of
mammals, and from the relative amounts of the two pairs of peptides and the
neurophysins it was suggested that they were derived from two common precursors
(14). This was shown to be correct by the use ofmolecular biology techniques to find
the entire amino acid sequences of both pro-vasopressin and pro-oxytocin (15, 16).
1.3 Magnocellular neurones in the hypothalamus - a site of
vasopressin synthesis and release
The classically described site of vasopressin and oxytocin gene expression is
in the hypothalamus. The hypothalamus, together with the posterior pituitary and
anterior pituitary glands comprises a fundamental endocrine structure. The
hypothalamo-pituitary axis and the basic unit of neurohypophyseal peptide
production - the magnocellular neurone - have emerged as paradigms for polypeptide
synthesis and secretion, and the study of the processes involved in the mature
expression of this phenotype proceeds on that basis (17). It is a feature of eukaryotic
cells that they possess an ordered and efficient production pathway for the synthesis
and trafficking of proteins, and this is shown to full effect by these neurones.
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Essentially they are neuroendocrine cells, capable of both the propagation of
action potentials and the secretion of hormones. These neurones possess large cell
bodies responsible for the production of vasopressin and oxytocin, and are found in
two paired groups (or nuclei) in the anterior hypothalamus, the supraoptic (SON) and
paraventricular (PVN) nuclei. Virtually all magnocellular neurones in both nuclei
project to the posterior pituitary. The SON contains three times the number of cells
as the PVN, but they both contain the same proportion of vasopressin- or oxytocin-
containing cells. Vasopressin and oxytocin are only very rarely found in the same
cell (18). The SON is typically much more homogenous than the PVN. The PVN
contains many subnuclei. As well as contributing magnocellular neurones to the
posterior pituitary subnuclei include some parvocellular neurones that whilst they
also synthesise vasopressin, project to other structures in the brain.
Axons of magnocellular neurones lead down the pituitary stalk to the
posterior pituitary gland. This gland is the site for direct entry of neuroendocrine
substances into the systemic circulation. The nerve terminals are situated
immediately adjacent to capillaries. Excitation of the neurone leads to fusion of
secretory granules with the plasma membranes and the emptying of their contents
into the extracellular or perivascular space.
Vasopressin and oxytocin are rarely found in the same cell (18). The reason
for this is not clear, but it appears that there are specific factors involved in the
phenotypic determination and growth of the neurones at the onset of their
development (19, 20). Vasopressin immunoreactivity can be detected in the posterior
pituitary early in foetal development (21, 22).
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Control of gene expression operates on several levels. Osmotic stimuli such
as dehydration or salt loading result in increased transcription (and thus AVP
messenger ribonucleic acid (mRNA) abundance) and an increase in poly-A tail
length on the transcripts. The precise machinery behind this control has not yet been
fully elucidated (23).
Vasopressin, an amidated nonapeptide, is initially translated as a
preprohormone. It is derived from this much larger translated precursor of 145 amino
acids. The vasopressin gene has been identified and sequenced in many mammalian
species. The gene is located on chromosome 20, and is linked closely to the oxytocin
gene. Divided into three exons, it is punctuated by two introns (24, 25). The first
exon encodes a signal peptide (ensuring correct trafficking of the primary translated
product), vasopressin itself, a bridging tripeptide, and the N-terminal sequence of the
protein called the neurophysin. The second exon encodes the main body of the
neurophysin (up to amino acid 76 of 93/95 amino acids). The third exon encodes for
the C-terminal sequence and a small glycopeptide of 39 amino acids, also known as
vasopressin-associated glycopeptide (VAG) or copeptide. As translated mRNA is
transported into the endoplasmic reticulum, the signal peptide is cleaved from the
peptide. Processing in the Golgi apparatus of the smooth endoplasmic reticulum
packages the prohormone into secretory vesicles for transport through the axon to the
posterior pituitary. During this transport the prohormone is subjected to enzymatic
changes that result in the final product of alpha-amidated nonapeptide. This
maturation involves a cascade of at least 4 enzymes that operate at the tripeptide
signal between the peptide and the neurophysin and the single amino acid connecting
the neurophysin and the glycopeptide - shown in Figure 1.1. First, a dibasic
10




The signal peptide is cleaved to generate prohormone, which is cleaved at two points by a
























FIGURE 1.1 Processing events in the synthesis ofmature vasopressin
(Adapted from 26)
Vasopressin is synthesised with neurophysin and a glycopeptide, together










endopeptidase cleaves the Lysine (Lys)-Arginine (Arg) bond, separating the
neurophysin and creating a twelve amino acid intermediary product. Next a
carboxypeptidase B-like enzyme (carboxypeptidase E or H) cleaves these two basic
residues, leaving a decapeptide. Then peptidyl-glycine alpha-amidating
monooxygenase (PAM - a single molecule which has two enzyme functions) acts on
the glycine residue at position ten to leave a peptidylhydroxyl glycine, which is in
turn split off by the second portion of the same enzyme which acts as a lyase
enzyme, resulting in the amine group attached to the now mature peptide and free
glyoxic acid (26). This processing is 95% complete before the arrival of the secretory
granule at the terminal bud, so that only mature peptides are found in the posterior
pituitary (27).
In mammals, vasopressin originating in the posterior pituitary gland is
involved in the homeostasis of the osmotic pressure of body fluids. Osmolality is
maintained at a constant level on an hour to hour basis, and severe alterations caused
by a lack of control by vasopressin exerted by can lead to trauma caused by changes
in the volume of the brain, and even death (28). To achieve the control of plasma
osmolality, vasopressin must respond to small changes. Cells sensitive to very small
changes in extra cellular fluid osmolality (osmoreceptors) present on the
anteroventral aspect of the third ventricle and outside the influence of the blood brain
barrier (29, 30) are thought to be responsible (as little as a 2% rise in plasma
osmolality can cause a drop in urine output (31)) by acting as stimulus for the release
of vasopressin.
In addition, blood volume depletion of more than 10% and rapid drops in
blood pressure will also cause a rise in plasma vasopressin. Volume responses are
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initiated by receptors in the left atrium, and it is thought that pressure changes are
detected by baroreceptors in the carotid sinus (32). Both osmotic and non-osmotic
stimuli cause the release of vasopressin via neural mechanisms. Action potentials are
propagated from the receptor cells to the magnocellular neurones causing a
depolarisation of the axon terminals in the posterior pituitary gland. This in turn
causes the influx of calcium ions (Ca2+) which brings about the exocytosis of
vasopressin - the fusion of neurosecretory vesicles with the cytoplasmic membrane
causing the contents to be released into the extra cellular space. Magnocellular
neurones terminate adjacent to capillaries which allow the contents of the vesicle to
be released directly into the blood stream (33).
1.4 Signal transduction of vasopressin
All actions of vasopressin are caused by binding of vasopressin to receptors
present in the surface membrane of the targeted cells. The receptors activate
cytoplasmic second messenger cascades to transduce the initial signal at the
molecular level. Three recognised receptors have been identified; the V2 receptor,
and two subtypes of the VI receptor - the Vlb receptor and the Via receptor. The V2
and the VI-type receptors activate different second messenger cascades, and so
expression of more than one type of receptor will, upon activation by vasopressin,
lead to different effects being caused, with different time courses, in the same cell.
Originally the receptors were identified as being two separate types, as the different
types have different affinities for analogues (34), and the VI-type receptors were
further subdivided by their pharmacological affinities for different analogues ofAVP
(35). Subsequently, molecular biological techniques have confirmed that although
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they share a common structural motif - neurohyophyseal receptors collectively have
a 35-60% amino acid sequence homology, and can be considered a subfamily of the
seven transmembrane span G-protein coupled receptors (GPCRs) (36, 37) - they are
different proteins.
1.4.1 V2 type receptor
The vasopressin receptor that mediates the classically recognised antidiuretic
hormone action has been designated the V2 receptor (34). Binding of vasopressin to
this receptor results in water re-absorption in the collecting duct of the kidney. The
receptor activates adenyl cyclase, leading to the production of cyclic AMP (cAMP),
which in turn activates protein kinase A. This enzyme causes the increased insertion
of aquaporin molecules, water channels through which osmotically driven water
molecules can pass from the collecting ducts into the interstitium (38). The human
receptor has been localised to the X chromosome (39). It is predicted to be a 371
amino acid protein with a molecular weight of approximately 40.2kDa (40). The rat
receptor is predicted to be a 370 amino acid protein with a molecular weight of
40kDa (41).
1.4.2 V1 -type receptors
V1 -type receptors are activated by the binding of the hormone to the cognate
region on the receptor. Acummulation of cAMP is not observed after V-l type
receptor activation (42). Instead, these receptors promote the exchange of GDP for
GTP at the binding sites of G-proteins, facilitating the G-protein catalysed activation
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of phospholipases C, D and A2 - enzymes capable of breaking down phospholipids
into constituent molecules (43).
Phospholipase C catalyses the breakdown of inositol phospholipids into
inositol phosphates - most commonly inositol 1,4,5-triphosphate (IP3) - and 1,2-
diacylglycerol (DAG) (42). IP3 causes release of calcium stores in the endoplasmic
reticulum, resulting in a transient increase in intracellular calcium concentration.
DAG activates protein kinase C, an enzyme that activates many proteins by
phosphorylation of specific residues in target proteins involved in cellular responses
to hormone signals (44, 45). The Na+-H+ exchanger is also activated in certain cells
(35, 46).
Phospholipase A2 produces arachadonic acid, which in turn is used to
generate prostaglandins and thromboxanes (46), as well as enhancing movement of
calcium ions into the cell from outside and from calcium stores with in the cell (35).
Phospholipase D catalysed breakdown products include phosphatidic acid,
which can alter the activity within the Ras pathway, or when broken down further
produces DAG (35).
1.4.2.1 Vlb receptor
Vasopressin stimulates the release of adrenocorticotropic hormone (ACTH)
from the anterior pituitary, and therefore participates in the stress-induced ACTH
surge. The transduction of vasopressin binding to the Vlb receptor is coupled to
different G-proteins depending on the concentration of receptors resident in the
membrane. At low concentrations the receptor couples to the Gq/n subtype. At higher
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densities the receptor can interact with both the Gj and GS; and thereby activate
several different signalling pathways (42).
The human Vlb receptor is predicted to be a 424 amino acid protein with a
molecular weight of approximately 47kDa (47, 48). Northern blot analysis by this
group (48) failed to find evidence of the transcript in any human tissues apart from
the pituitary gland (site of ACTH release), the tissues tested being heart, brain, lung,
placenta, skeletal muscle, pancreas, kidney, and liver. However, a faint signal was
present in mouse tissues, those tested being hypothalamus, brain, adrenal, pancreas
and colon (49)
Rat tissues have also been analysed by the use of reverse transcriptase-
polymerase chain reaction (RT-PCR) and found Vlb expression in the thymus, heart,
lung, spleen, kidney, uterus and breast. This report also stated that Vlb mRNA was
not detected in the liver, adrenal gland (they do not specify whether cortex or
medulla was used), seminal vesicles and testis (50). RT-PCR studies of the pancreas
revealed a positive signal for this receptor (49).
1.4.2.2 Via receptor
The Via receptor designation was created as a consequence of the
recognition of the Vlb subtype and its different pharmacological profile (51). Via
receptors are coupled to a G-protein (52) - primarily the Gq/n subtype (42) but also
the Gj subtype (53). Secondary nuclear signal mechanisms that are activated by
binding of vasopressin to the V1 a receptor include the induction of immediate-early
response genes expression, causing protein synthesis which culminates in
hypertrophy and increased protein content of the cell (54). Other recognised actions
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include blood vessel constriction, liver glycogenolysis, platelet adhesion, stimulation
of adrenal gland secretion, and certain brain functions.
The gene (a single copy) for the Via receptor has been localised to
chromosome 20 (55). cDNA sequences for the human receptor predict a 418 amino
acid segment of the receptor of approximately 47kDa molecular weight (56). cDNA
sequences for the rat receptor predict a 394 amino acid segment of approximately
44.2kDa molecular weight (41). However, reports of the molecular weight of the
receptor using other methods differ, and it may be that these estimates are affected
by dimerisation and glycosylation of the receptor. One of the first estimates of the
weight of the rat Via receptor using migration in sucrose density centrifugation was
83kDa (57); double what might be expected. Whilst Western blotting analysis led to
an estimate of 44.2kDa in rat tissues (58), it is clear that the receptor is glycosylated
in its fully matured form. A photoprobe with high affinity for the receptor was used
to produce an estimate of 53kDa for the rat receptor, and treatment with a
deglycosylation enzyme reduced this estimate to 43kDa (59).
The Via has four consensus sites that may potentially be glycosylated, and
three of them are reported to be used in translation and processing of the rat Via
receptor (37). Interestingly though, these studies also revealed that the glycosylation
was not important for the function of the receptor. Mutated receptors lacking the
glycosylation were not expressed with lower efficiency, bound analogues of AVP
with the same affinity and specificity as the wild type receptor, and participated in
cell signalling cascades fully. However, Via receptors show variation in their
affinity for different ligands between species, and so this may not be the case for all
species.
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Using Northern blot analysis, mRNA coding for the Via receptor has been
demonstrated in the liver, heart, kidney and skeletal muscle in human tissues (55).
The Northern blot analysis of rat tissues obtained positive results in the liver, kidney,
spleen, and testis (41, 60). But the expression of the Via is species specific and has a
developmental aspect to it. Whilst the commonly studied rat expresses ample Via
receptor in the liver, human (61), rabbit (62), and sheep (63) liver have been shown
to show almost a complete lack of these receptors, and their participation in
regulating hepatic function in these species has been questioned.
Of relevance to this thesis is the specific developmental expression of the
Via receptor. In the rat liver, Via receptor is not seen before birth, and the authors
point out that this means that the liver is not a target for vasopressin at this stage of
development (although vasopressin is detected prenatally) (64). After birth, when the
now independent rat is solely responsible for control of glucose levels, expression of
Via mRNa and translation of this message into functional receptor is rapid. In rat
testicular myoid cells, Via receptor is not seen before puberty, but is present in adult
cells where it potentially plays a role in regulation of testicular function (65). These
two studies serve to establish a principle, that expression of the Via receptor is
tightly controlled in order to allow specificity in the action of AVP. On the evidence
of these two studies, there is not a case to be made for proposing that Via receptor is
generally expressed in many tissues types with no specific role in the function of that
tissue.
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1.5 Evolution of vasopressin and cognate receptors
The effects of vasopressin are widespread, and are mediated by the receptors
discussed in Section 1.4. Oxytocin, and the single receptor type that recognises it, are
not described in this section, and this should reflect the point that the
neurohypophyseal peptides are a group of distinct peptides with distinct actions, that
occur through the mediation of distinct receptors.
Diversity in the neurohypophyseal hormones in different species was
demonstrated before the molecular structure of any peptide was actually known.
Heller showed this by comparing the relative activities of standardised amounts of
posterior pituitary extracts in bioassays (66). The fact that extracts from different
animals had different potencies in the same conditions meant that the relevant
components of the extracts had to be structurally different in some significant way
that a receptor in the bioassay recognised the molecules with different affinities and
potencies. The ability to synthesise peptides and in particular the description of
vasopressin and oxytocin was a key to the further investigation of these related
peptides. In some cases, peptides have been speculatively synthesised before their
presence has been demonstrated in an organism. Sawyer recounts an instance of this
(67). Katsoyannis and du Vignead had synthesised a hybrid peptide consisting of the
ring of oxytocin and the tail of vasopressin, and named it arginine vasotocin (AVT)
(68). Munsick and colleagues (of which Sawyer was one), studying a peptide
contained in extracts from chicken neurohypophysis found that the peptide behaved
exactly like the synthesised peptide when subjected to chromatography and chemical
analysis (69). This was later confirmed when Heller and Pickering chemically
characterised and identified AVT in non-mammalian pituitary glands (70).
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To date, thirteen neurohypophyseal hormones have been identified (71). The
conservation of amino acid sequence and, therefore, structure is remarkable (see
Table 1.1). Within the limits of larger requirements for intrinsic stability of the
molecule, the variation of the peptides must also be limited by the requirement that
the peptide fits to a specific receptor. (If the variation is large so as to not be
recognised by the receptor, it must a non-functional mutation and presumably not
likely to be of any improvement on the previous peptide.) They are all
nonapepetides, and they all have a disulphide bridge (involving two cysteine
residues) between positions 1 and 6. The amino acids at position 2 and 3 are always
hydrophobic, and those at 4 and 5 are always polar. Of the three tail amino acids, 7
and 9 are invariant, apparently supplying a protective conformation against
degradation and structural rigidity to the molecule (11). The variations are only seen
at amino acid positions 3,4 and 8. Three dimensional structural predictions based on
deaminoxytocin show how substitutions at these positions can change the specific
identity without radically modifying the general conformation (72). For example,
vasopressin-like peptides have a basic residue (Arg or Lys) at position 8, whereas
oxytocin-like peptides virtually always have a neutral aliphatic hydrophobic residue
at this position. The biological significance of such substitutions are clearly shown
by the transformation of AVT to AVP. Replacement of isoleucine by phenylalanine
at position 3 gives rise to a peptide that acts only on the kidney and vascular
receptors, but not on uterus and mammary gland receptors (as AVT also does).
As a result of this stability within the small confines of a nine amino acid
peptide, they are limited in their value as a basis for delineating phylogenetic
relationships established by other methods. Much better candidates for such a
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NH2- 123456789 COOH
Basic structure Cys Tyr • Gin Asn Cys Pro * Gin
Arginine vasopressin (AVP) Phe Arg
Lysine vasopressin (LVP) Phe Lys
Arginine vasotocin (AVT) lie Arg
Oxytocin (OT) lie Leu
TABLE 1.1 Chemical structure of mammalian neurohypophyseal hormones
The backbone of the peptides, a nine amino acid peptide consisting of a six
amino acid ring (linked by cysteine residues) with a three amino acid tail, is a consistent
motif not only in mammals but all families shown to express forms of this peptide. The
structural similarity of the peptide hormones provides information as to the evolution of
function of the hormones, and demonstrates the remarkable specifcity of receptors to
particular peptides to discern them from others present in the body.
•
- indicates positions of amino acids substitutions
Arg = Arginine Gin = Glutamine Phe = Phenylalanine
Asn = Asparagine lie = Isoleucine Pro = Proline
Cys = Cysteine Leu = Leucine Tyr = Tyrosine
Lys = Lysine
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process are proteins such as mitochondrial cytochrome c, where there is sufficient
significant change between species and orders to distinguish them and construct
time-line relationships between them on the basis of the enzymes' primary structures
(73).
But changes have occurred to the neurohypophyseal peptide gene throughout
evolution. In fresh water Hydra, which possess the most primitive nervous system
known and does not have a feature comparable to blood, the presence of not only
vasopressin/OT-like immunoreactivity but also gastrin/cholecystokinin, Substance P,
neurotensin and bombesin/gastrin-releasing peptide-like immunoreactivity have been
demonstrated. This suggests that peptides played a role as neurotransmitters long
before being 'recruited' as hormones in 'more evolved' species (11). AVP/OT-like
immunoreactivity has been found in various classes of invertebrates (74-76). Their
functions are largely unknown. However, there is no evidence for the co-existence of
both vasopressin-like and oxytocin-like immunoreactivity in the same invertebrate
species. Thus, a single copy of the gene is present in the genome at that point in
phylogenetic development.
Neurohypophyseal peptides are found in all vertebrates. The most 'primitive'
vertebrates, the cyclostomes, apparently only express a single peptide, AVT. This
seems to suggest that AVT is the original ancestral gene of both arginine vasopressin
and oxytocin, which are apparently the most recent transformations of the
neurohypophyseal peptides. This also suggests that the existence of the two different
peptide types in the same organism in subsequent lines of phylogenetic development
is the result of a gene duplication event (77). Such events are central mechanisms in
the generation of functional diversity and shifts or additions of function (78). Gene
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duplication is also the mechanism by which the subtypes of vasopressin receptor
were most likely to have been generated (11).
The evolution of the peptides and their receptors seems to be an example of
co-evolution (79). All species that express a neurohypophyseal (or NHP-like) peptide
also express an associated receptor that has significant sequence homology with
other member of the G-protein linked receptor group but is strongly specific for that
particular peptide. The phylogenetic point at which this duplication occurred is not
clear. Similarly, the first physiological function of the vasopressin precursor in
vertebrates can only be speculated on. Since AVT affects cardiovascular function in
non-mammalian vertebrates, and vasotocin receptors are distributed throughout the
cardiovascular system in these animals, Saywer suggests that the most primitive
functions of vasotocin are related to cardiovascular regulation (77).
Darlison and Richter examined many examples of multiple receptor types in
a single genome and concluded that receptors evolved as a result ofmutations of the
peptide; a subsequent change in the receptor then conferred specificity to the initial
change in the structure of the peptide (80). Viable mutations would have to retain
some affinity for the original receptor, and receptor mutations would have to
similarly be able to recognise one or both of the peptides. But through this process,
and that of gene duplication, different responses could be mediated by different
receptors responding to the same peptide.
But the principle is established that the gene coding for the original peptide,
the processing enzymes that are able to produce a mature translation product, and a
receptor specific to the peptide, existed before the invertebrate/vertebrate divergence.
That the precursors to vasopressin had functions of physiological significance before
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the emergence of the neurohypophysis as an anatomical structure also establishes a
principle central to this thesis. It is perhaps better to use the phrase 'diversity of
action' rather than the word 'function', for at a very simplistic level the function of
the neurohypophyseal peptides is to bind to their respective receptors, and the
function of the receptors is to transduce the event of binding into a biochemical
signal with the cell. This is invariant throughout the range of examples of the
peptides. The change that is manifested is in the tissues and responses that the
peptide and receptor mediates. It is proposed that the ancestral vasopressin-like
molecule was a neurotransmitter in the first instance of the ability of a peptide to
exert a biochemical change (76). At the other end of the phylogenetic tree,
vasopressin (lysine and arginine) is the antidiuretic hormone and oxytocin is
involved with parturition and the milk let-down reflex. Along the way, the peptides
have undergone a change in the site of synthesis, and therefore a change in their
mode of action, from local neurotransmitter to endocrine hormone. It should
therefore be obvious to state that there has been a change in the tissues the peptides
exert an effect on, and a change in the effect they cause.
Sawyer speculates that the presence of vasopressin receptor in the blood
vessels might serve no physiological function, on the grounds that maximal
antidiuresis is achieved at plasma concentrations of vasopressin well below those
that have an effect on blood pressure, and the receptors are "merely vestigial
reminders of our evolutionary history" (77). Whilst perhaps not agreeing with the
example chosen, the point is clear - there are circumstances in which in vitro effects
of vasopressin are seen, but at concentrations that cannot be matched by any
observed in samples of blood plasma. Such an in vitro observation can be viewed in
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two ways, as an artefact of the in vitro system, or as a genuine phenomenon. Just as
the levels of blood vasopressin are not high enough to cause the in vitro effect in situ,
so the system exerting the control might not be seen when examining whole body
preparations. That is to say the action is paracrine or autocrine in nature, and
concentrations required to cause the effect are not reflected blood plasma levels. In
short, observations like those of Sawyer argue for the synthesis of vasopressin in
areas other than the hypothalamus. This is entirely in keeping with the origin of this
molecule - it was a non-hypothalamic regulatory peptide, and the processing
machinery required to generate active peptide should be able to operate normally in
such situations. Examples of proposed alternative sites of synthesis are described
below.
There should, therefore, be no surprise to find AVP involved in the process of
cancer. Viewing vasopressin purely as a regulatory hormone denies the progression
in development of action that leads to the arrival at its present roles. Examples of
vasopressin acting as a growth promoter in tissues are common, and some of these
are discussed. One way of viewing causes of cancerous growth is the result of
inappropriate and uncontrolled expression of growth factors in tissues, rather than the
occurrence of an aberrant and novel function (81). The involvement of vasopressin in
certain types of cancer could be viewed as a example of this uncontrolled expression,
a recapitulation of the ability of the peptide to exert an effect that predates the one it
is predominantly associated with in mammals (82-84).
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1.6 Alternative sites of synthesis and local action of vasopressin
It has been stated (85) that the first demonstration of extrahypothalamic
vasopressin immunoreactivity was by Wathes et al in the human ovary (86).
However, earlier reports of the detection of neurophysin-like material in the uterus
and pineal gland predate this as an example of NHP peptide localisation in
extrahypothalamic areas (87). The significance of these earlier reports were often
downplayed in the concluding comments, perhaps due to some resistance to the idea
that NHP peptides could be anything other than the neurohypophyseal peptides (a
good example of this attitude is a later article entitled "Is the evidence for ectopic
antidiuretic hormone watertight?" (88)).
Reports of concentrated vasopressin immunoreactivity are often attributed to
sequestration of the peptide by specific factors. An example of uptake of vasopressin
to produce local AVP concentrations above that of circulating plasma levels is that
seen in the pituitary and pineal glands (89). Another often cited example of
sequestration of AVP is that carried out by blood platelets. These cells are involved
in blood clotting and wound repair processes, and are derived from mononuclear
cells. Approximately 90% of circulating AVP is 'associated' with platelets (90).
AVP immunoreactivity extracted from platelets was seen to behave in exactly the
same way as peptide extracted from the posterior pituitary - it diluted in parallel to
AVP reference standard in a radioimmunoassay (RIA) of the peptide, and it had the
same retention time on a high perfomacne liquid chromatography (HPLC) column as
synthetic peptide. Tellingly, a bioassay was performed, and the extracted AVP was
biologically active in the rat assay for antidiuretic activity (91).
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When exogenous AVP was infused into human subjects, a significant
increase in both plasma and platelet-associated AVP was found. This increase
occurred in a consistently proportional manner to provide an equation for the
distribution of immunoreactivity (plasma AVP = 2.48 + 0.11 platelet AVP).
Additionally, patients with idiopathic and post-surgical diabetes insipidus were seen
to possess negligible platelet AVP. All these data suggest that the AVP associated
with platelets is taken up from plasma and originates from the hypothalamus. Despite
there being a similar blood plasma concentration of oxytocin, no oxytocin appears to
be associated with platelets.
Berretini described a specific saturable binding of 12"I-AVP to human
platelets, which showed specificity characteristic of V2-type receptors (92).
However, when Vittet and colleagues compared the binding of 3H-AVP to
membranes prepared from human platelets and rat liver and kidney, it was found that
the binding characteristics of platelet preparations were comparable to those of liver
membranes but not the kidney membranes (93). This was backed up by the affinities
the preparations showed for different vasopressin analogues. Thibonnier confirmed
the receptor on platelets was similar to the Vla-type receptor (94).
Vasopressin was shown in vitro to promote the aggregation of human
platelets (93). Binding of vasopressin with platelet membranes stimulated the
phosphorylation of two calcium-dependant proteins (94). The peptide has been
shown to activate platelets, leading to adhesion, aggregation and secretion, but
originally this was seen only at concentrations of vasopressin many orders of
magnitude above the free plasma concentrations for normal humans (94, 95).
However, using flow cytometry and monoclonal antibodies to identify specific
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proteins, Wun and colleagues demonstrated activation of platelets after incubation
with physiological concentrations of vasopressin (95). It is speculated that platelet
binding of vasopressin may play a role in the rapid clearance of the hormone from
the circulation, or more plausibly that this uptake may indicate a role in modulating
platelet function. Vasopressin is released in situations of stress, and the activation of
platelets in situations which potentially involve acute blood loss is consistent with a
role for vasopressin in the mediation of stress responses. Thus, vasopressin can be
seen to be concentrated from sources containing normal, low levels of the peptide,
perhaps to achieve the concentrations required to activate the second messenger
cascade of the receptor.
Two reviews authored with the aim of discussing the idea of
extrahypothalamic NHP peptides strike a note of caution at inferring physiological
significance to observations of direct vasopressin and oxytocin immunoreactivity in
peripheral tissues (85, 96). Murphy and co-authors assert that the evidence of a
positive result by Northern analysis should not be interpreted blindly as proof of an
active, translated product. The example supplied is the positive result gained in
experiments on testis tissues. Transcript isolated from testis tissue was shown to lack
the vasopressin encoding exon, and although small amounts of the full transcript
could be found, the authors concluded that with evidence available the levels of
transcript were too low to be of undoubted physiological significance.
The many methods used in the investigation of peripheral and non-
magnocellular neuronal synthesis of vasopressin are also reviewed. Despite the
reservations expressed by the authors, the vast majority of the studies cited do not
use molecular biological techniques as the primary source of data. Instead,
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immunological methods of detection are employed; usually immunohistochemistry
or radioimmunoassay. More sensitive methods that could be used, such as in situ
hybridisation, Northern blotting and use of RT-PCR, are only employed in studies
following initial immunological studies.
A crucial point is this conclusion:
"Only in one non-pathological case, the expression by the bovine ovary of
oxytocin, does peripheral expression result in an elevation of plasma hormones
levels, which could have systemic effects and be of physiological significance....
...for all other instances of extrahypothalamic VP and oxytocin gene expression, we
are reduced to postulations involving subtle autocrine or paracrine functions" (96)
This conclusion seems to seek to emphasise the position that only circulating
levels of vasopressin have "physiological significance", only validating those
functions that are regulated by circulating vasopressin itself. It is hoped that in the
examples shown below, it is clear that basal plasma levels of vasopressin have no
relevance to the action of vasopressin at the local level, at least in the periphery,
where vasopressin is seen to act as a paracrine or autocrine hormone and supplies
levels of vasopressin that cannot commonly be created in the circulation.
The point is well made, however, that there are certain conditions that must
be fulfilled for a cell or tissue to express an active vasopressin molecule, and one that
functions in the local environment. Essentially they are the same requirements
embodied by the expression of vasopressin in the magnocellular neurones of the
hypothalamus. Transcription factors must be present in order to promote gene
transcription to provide a full mRNA that can be translated into the peptide itself, the
neurophysin and the VAG. Processing enzymes must be present to produce an active
final product from the translation. Beyond that, it would seem desirable that the
peptide be packaged in a way that it can be released, that is to say within a secretory
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vesicle. Also, the tissue should be shown to possess functional receptors to
vasopressin in order that this signal be transduced and exert an effect. It would seem
logical to suggest from these criteria that cells equipped to synthesise other peptides
are better candidates for sites of vasopressin synthesis than those that are not. Such a
theory is in adherence with the contention that polypeptide synthesising cells are
derived from the same embryonic layer, the neural crest (97). Pearse calls these cells
APUD cells (Amine Precursor Uptake and Decarboxylation). It is a compelling
theory, but evidence to demonstrate exceptions is widespread (98). Debate on this
matter is ongoing. Until the matter is more satisfactorily resolved, it cannot be
discussed in the context of description of tissues that are proposed to synthesise
vasopressin beyond agreement with the proponents of a wider source of endocrine
cells. It seems better to say that these cells share biochemical features that are
acquired through differentiation rather than embryological programming (99).
The cases of non-magnocellular neuronal production of vasopressin are
reviewed below. Where possible, the criteria listed above are addressed in the case of
each tissue. As will be seen, however, there are few tissues in which a full
investigation has been carried out. The question of the processing enzymes being
present in cells is rarely addressed. As a result, there is clearly a division between
neuronal cells (that are assumed to possess the requisite enzyme through their
phenotype) where the vasopressin presumably acts as a neurotransmitter and so
stimulates structures with well defined roles, and other tissues (whatever designation
the cells within tissues that produce vasopressin eventually receive) where the role of
the peptide is less clear beyond activating resident receptors, and so the two areas of
observation are dealt with separately.
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1.6.1 Vasopressin in brain tissue
1.6.1.1 Vasopressin within the hypothalamus
Within the hypothalamus itself, parvocellular neurones situated in the
paraventricular and suprachiasmatic nuclei, which project to a number of regions in
the brain, synthesise active vasopressin (100). Some of these neurones terminate in
the median eminence, where vasopressin is released into the portal system that drains
into the anterior pituitary gland. Vasopressin from these neurones acts as a releasing
factor for adrenocorticotropic hormone (ACTH). Thus, vasopressin is intimately
involved with the stress response. Other neurones are found ending in the medial
septum where vasopressin is thought to play a role in antipyresis. (101, 102).
Neurones terminating in the spinal cord are thought to be involved with regulation of
blood pressure (103). Vasopressin originating in the parvocellular neurones of the
suprachiasmatic nucleus is also thought play role in circadian control (104).
1.6.1.2 Vasopressin in brain tissue beyond the hypothalamus
Vasopressin immunoreactivity has been demonstrated in several regions of
the brain. Vasopressin immunoreactivity and vasopressin mRNA have been
demonstrated in the medial amygdala and bed nucleus of the stria terminalis. Axons
from these nuclei project to various regions of the brain such as the lateral septum,
diagonal band of Broca, locus coerulus, amygdala and ventral hippocampus (105).
The lateral septum mediates the effect of vasopressin on body temperature, the
amygdala and ventral hippocampus have roles in learning and memory. Vasopressin
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has been shown to facilitate memory consolidation and retrieval in rats (106, 107). In
humans vasopressin was shown to be a contributing factor in the improvement of
memory, a function that essentially relies on hippocampal function.
Vasopressin has also been demonstrated in the pineal gland of the rat (108),
sheep (108), and cow (109). Neurophysin-like immunoreactivity and activity was
detected in the human pineal gland (87). In the rat, the levels of pineal vasopressin
were shown to vary according to the season, with a high in the summer months
(108), a variation not seen in hypothalamic levels of vasopressin mRNA or pituitary
levels of vasopressin (110). Vasopressin mRNA has been demonstrated by in situ
hybridisation histochemistry in cells in the pineal gland (111). The active peptide
generated in this gland probably has some intraglandular activity because Vla-type
receptor mRNA has been detected in adult male rat pineal cells (112). Vasopressin
binding was also demonstrated in pineal glands from the rat, which was shown to be
saturable and specific to the Via receptor subtype (113). This study also
demonstrated that vasopressin potentiated noradrenergic secretion of melatonin (and
this was inhibited by a Via antagonist). The authors concluded that vasopressin
could be a locally synthesised modulator of rat pineal synthetic activity exerting an
influence through the Via receptor subtype.
1.6.2 Vasopressin in peripheral tissues
It is interesting to note that there are many descriptions of neurohypophyseal
peptides in peripheral tissues, and in many of these cases any vasopressin
immunoreactivity is accompanied by oxytocin immunoreactivity. The relative
abundance of the two peptides is stated where possible, as is any proposed function
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for vasopressin. In most cases the peptide that was found in greater amounts goes on
to be the focus of study in that tissue, and thus a role for one but not the other is
usually designated. An exception to this is the case of the adrenal gland where early
reports indicated greater concentrations of oxytocin than vasopressin, but far more
research has gone into elucidating the role of vasopressin in this tissue.
1.6.2.1 Vasculature
Vasopressin immunoreactivity that behaved like synthetic vasopressin in
radioimmunoassay and HPLC was extracted from various rat blood vessels and
bovine aorta (114). Because of the potential risk for contamination by blood in
samples, the researchers took painstaking measures to clarify that this was not the
case. Levels of vasopressin extracted from blood vessels were the same in
hypophysectomised rats and Brattleboro rats (114). mRNA for vasopressin was
identified in both normal (115, 116) and Brattleboro rats (117). The vasopressin Via
receptor is widely expressed in blood vessels and has been shown to be involved in
control of blood pressure in situations of haemorrhage, so the role of a locally acting
higher concentration of vasopressin is obscure. Vasopressin is a hypertrophic (but
not proliferative) agent for cultured smooth muscle cells, and it may be that
vasopressin plays a role in the growth of vascular smooth muscle (118, 119).
1.6.2.2 Sympathetic nervous system
There is one report of a vasopressin-like peptide (VLP) in the rat superior
cervical and celiac ganglia (120). This immunoreactive substance eluted after the
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elution of one void volume, and not with synthetic AVP. Importantly however, when
extracted VLP was injected into water loaded rats, that extract was antidiuretic, but
had no effect on blood pressure. The authors speculate that VLP is responsible for
many of the non-adrenergic responses observed after stimulation of the sympathetic
nervous system. Although this novel molecule was shown to have this antidiuretic
bioactivity, and have such great potential for neuronal control, no further work seems
to have been done to develop these observations.
1.6.2.3 Ovary
The first demonstration of vasopressin immunoreactivity in peripheral tissues
was by Wathes et al in the human ovary (85, 86), subsequent to observations of
larger amounts of oxytocin immunoreactivity (reviewed in (121)). Immunoreactivity
was detected at the same elution volume as synthetic vasopressin when subjected to
Sephadex G-50 gel filtration. AVP-ir was also shown in the Brattleboro rat corpus
luteum (122). Additionally, such immunoreactivity was shown to be 10-fold higher
in the adult than that detected in immature rats (122).
mRNA coding for the vasopressin neurophysin has been detected in the
ovaries of both Long Evans wild type and Brattleboro rats (123), but gene transcripts
analysed by Morley and Ivell could not yield a viable translation product (124). It
has been proposed that vasopressin has a role in steroid synthesis regulation in the rat
(85), but it seems that oxytocin is the more important NHP peptide in the ovary, and
accordingly much more work has been carried out to elucidate mechanisms of
expression of that peptide (125). Certainly, no reports of vasopressin receptors in the
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ovary could be found when searches were carried out on the literature databases
PubMed and Ovid.
1.6.2.4 Uterus
Immunoreactivity specific to vasopressin and oxytocin and their associated
neurophysins extracted from rat uterine tissue was characterised. AVP and oxytocin
immunoreactivity was shown to have identical mobility with synthetic peptides. The
neurophysin immunoreactivity was subjected to a variety of physical separation
techniques (gel chromatography, gel electrophoresis, isoelectric focusing) and
behaved in the same way as neurophysins extracted from the posterior pituitary gland
(126). The neurophysin was also localised to epithelial cells lining the uterus by
immunohistochemistry, and was show to be present in uterine fluid, suggesting
secretion (126). In non-pregnant humans, vasopressin levels were higher than those
of oxytocin, but not significantly. (127). No reports of the detection of vasopressin
mRNA could be found.
The V1 a-type receptor was identified in uterine tissue from pregnant rabbits
(128) and pregnant humans (129). The mRNA for this receptor has also been
identified (130). Levels of the mRNA were shown not to vary throughout gestation
(131).
Vasopressin was shown to exert a potent effect on uterine vascular smooth
muscle (132), and it is suggested that vasopressin is an important factor in
myometrial hyperactivity, uterine ischemia and pain of primary dysmenorrhea as
well as regulating blood flow in non-pathological states (133). This is in contrast to
oxytocin, which is thought to be involved in the course of labour since an increase in
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oxytocin receptors is observed in the uterus just before parturition, and changes in
receptor levels are observed at different stages of the menstrual cycle (134).
However, activation of the receptors at parturition does not seem to be a function of
locally produced oxytocin (135), and the role of the locally produced peptide remains
unclear (136, 137).
1.6.2.5 Testis
Vasopressin immunoreactivity has been demonstrated in extracts of testes
from the rat (Long Evans and Brattleboro), mouse, dog, and human (138, 139) that
was higher than could be accounted for by levels in the blood. The peptide could not
be detected however by immunocytochemistry (140). Neurophysin-like
immunoreactivity has also been detected in the rat and human testis (138),
suggesting that the source of the vasopressin was local synthesis. In addition
vasopressin degrading enzyme activity has been detected in extracted testes, which
the authors believe may be another necessary criteria for terminating the action of
locally produced vasopressin (139).
Accordingly, a faint signal was achieved when Northern blotting analysis was
used to probe for the vasopressin mRNA (141). This observation has been
successfully repeated by two other groups (142, 143). However, the majority of the
transcript that was detected by Lefebvre and Zingg (143) was shown to not contain
the vasopressin coding section. This was also demonstrated by PCR of cDNA clones
of the transcripts (obtained by differential hybridisation and RT-PCR) (144).
Nonetheless, a normal transcript was also detected (in lower levels undetectable by
Northern blot analysis), and has been detected in cultured Leydig cells (144), thus
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localising the site of production. A promoter element in the rat vasopressin gene
specific to transcription occurring in the testis has also been described (145).
With respect to the role vasopressin may play in the testis, the peptide has
been shown to inhibit gonadotropin-induced androgen biosynthesis in cultured cells
(146), and it has been proposed that vasopressin also acts to stimulate contractile
activity of the seminiferous tubules. In keeping with this, vasopressin receptors of the
Via subtype have been demonstrated to be present on Leydig cells and myoid cells
of the seminiferous tubules (65, 147, 148). Moreover, Howl and co-workers report
that the expression of the receptor on the myoid cells is a developmentally regulated
process (they are not apparent in the testis of immature rats), implying that
vasopressin has a role in the control of testicular function in the adult male rat.
1.6.2.6 Thymus
Vasopressin immunoreactivity was identified in thymus glands of the rat
(149) and human (150). Further, immunohistochemistry described in both these
studies localised the immunoreactivity to epithelial cells in both the cortex and the
medulla regions of the gland. mRNA encoding for vasopressin was identified (151).
The Vlb receptor has been identified in thymus tissue using RT-PCR (50). It is
thought that neuroendocrine peptides expressed by the cells have a role in the
negative selection of T-cells that recognise these peptides (152).
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1.6.2.7 Pancreas
Immunoreactive vasopressin and oxytocin have been demonstrated in rat and
human pancreas (153). Immunochemistry was able to localise both of the peptides to
the exocrine portion of the pancreas (154). However, there do not seem to be reports
on the presence of vasopressin mRNA in this tissue. A receptor was shown to be
present in the pancreas and was pharmacologically characterised as the VIb receptor
(155). This characterisation was supported by RT-PCR studies of the pancreas that
revealed a positive signal for this receptor (49). Infusion of vasopressin and oxytocin
stimulated the release of glucagon and insulin from the pancreas in the rat, dog, and
human (156-158), and so it would seem that vasopressin potentially plays a role in
modulating the activities of these hormones, perhaps in situations of stress (157).
1.6.2.8 Adrenal glands
By far the largest body of work on an extrahypothalamic source of
vasopressin is that which concerns the adrenal glands. Investigation into
neurohypophyseal hormones as possible components of the adrenal gland was
prompted by an earlier observation that these hormones were present in various areas
of the central nervous system (159). Oxytocin had been found in the
intermediolateral grey column of the human spinal cord, which is the site of origin of
the preganglionic neurones of the sympathetic nervous system (160). The discovery
that oxytocin was a component of the ovary prompted another group to look for
neurohypophyseal hormones in the testis, and they also examined foetal adrenal
glands for some unexplained reason (138).
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The first reports of vasopressin (and oxytocin) immunoreactivity in the
adrenals were published in 1984. Ang and Jenkins applied extracted rat adrenal
glands to a Sephadex G-50 column, and found specific immunoreactivity in the
fractions with retention volumes that were the same as for synthetic peptide (159).
HPLC was used to separate and identify the neurophysins- they too were detected.
Co-localisation of these two molecules suggested that the peptides were being
synthesised in the adrenal gland. The same group reported that vasopressin
immunoreactivity could be found in the adrenal glands of Brattleboro rats (161). The
extracted peptide was shown to be biologically active using a bioassay that measured
antidiuretic response in rats. Immunohistochemistry showed the peptide to be present
everywhere in the adrenal gland of the Brattleboro rat apart from the zona
glomerulosa. No description of detection of the neurophysin is included in this study,
which is interesting considering the mutation in the vasopressin gene that causes it to
be improperly translated is in the exon that encodes for the neurophysin (162).
However, another group showed small amounts of VAG immunoreactivity in some
cells of the Brattleboro rat adrenal medulla (163). Nicholson et al showed the
presence of both vasopressin and vasopressin-associated neurophysin in the foetal
human adrenal (138). This group drew the same conclusion - that co-localisation of
both the peptide and the neurophysin in high concentrations argued against their
sequestration from the blood.
Other investigators searched for the two peptides in the human and rat foetal
adrenal (164). It was theorised that the foetal adrenal might be an alternative source
for AVP found in amniotic fluid. Staining was seen in both the definitive cortex and
the foetal cortex. In addition, quantitative data supplied for the levels of AVP are
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orders ofmagnitude lower than those quoted by Nicholson (138), being in the range
of pg of peptide per g of tissue, as opposed to the 102 x pg of peptide per g of tissue.
Ravid and co-workers also report very low amounts of immunoreactivity obtained in
rat foetal adrenal glands extracts (164). Vasopressin and oxytocin have been
described in bovine adult adrenal medulla and cortex, although the proportions of
peptide to their respective neurophysin seemed to be variable depending on the tissue
examined (165). There was more vasopressin-associated neurophysin in the medulla,
despite the fact that equal amounts of vasopressin were observed for medulla and
cortex. The ratio of oxytocin to its neurophysin was far closer to molecular
equivalency, and they were both present in higher amounts in the medulla than
cortex. The biological activities for the extracted vasopressin and oxytocin were also
demonstrated in relevant bioassays. The same group examined four different species
and found different staining patterns in each (166). Their observation was that
staining was generally stronger in the cortex than the medulla, with the zona
glomerulosa displaying the strongest staining.
Using RT-PCR, a whole mRNA for the vasopressin gene was demonstrated
in the rat adrenal medulla (167). RT-PCR failed to show mRNA for vasopressin in
the rat adrenal cortex (168). Prohormone processing enzymes PCI/3 and PC2 have
been isolated from bovine (169) and rat (170) adrenal medulla chromaffin cells,
indicating that translated preprohormone could be processed in medulla.
It has also been demonstrated that human adrenal medulla chromaffin cells
secrete vasopressin under basal conditions (171). Corticotrophin-releasing hormone
(CRH) and acetylcholine (ACh) were both shown to stimulate the release of
vasopressin from the human adrenal medulla (172). Vasopressin secretion was also
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stimulated by ACh in the rat adrenal, but no effect was observed upon infusion of
CRH (the peptides are identical in the two species).
Vasopressin receptors have been demonstrated in both the cortex and the
medulla of the adrenal gland. Autoradiography demonstrated specific binding of
vasopressin in both the zona glomerulosa (173) and zona fasciculata (171) of the
human adrenal, with the density of binding two-fold higher in the zona fasciculata
(174). Pharmacological characterisation and RT-PCR products identified the
presence of only Via receptors in the cortex (171). Binding sites for vasopressin
were demonstrated in the bovine adrenal medulla (175). Taylor and colleagues
identified Vl-type receptors (176), and RT-PCR of medullary tissue indicated the
presence of both Via and Vlb receptors, with Via receptor present in far greater
numbers than the Vlb receptor (172). There are no reports of a specific location of
the receptors in the medulla, something the authors recommend is addressed as soon
as possible (172).
Infusion of human adrenal glands with vasopressin causes aldosterone and
Cortisol secretion. It was also found that vasopressin had a mitogenic effect on zona
glomerulosa cells (177, 178). In rats, it was found that although Via receptors were
present in both the outer zones of the cortex, the receptors in the zona fasciculata
were non-functional and unable to stimulate corticosterone secretion (172).
Incubation of cultured rat adrenal medulla cells with vasopressin was shown to cause
the release of locally stored catecholamines, CRH, and ACTH. (172, 179).
A theory as to the role of locally produced vasopressin is put forward by
Guillon and colleagues (172). Stimulation of the splancnic nerve causes the local
release of vasopressin. This causes the release ofCRH and ACTH from medulla cells
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(a system described as a duplicate of the one seen in the anterior pituitary (180)),
Cortisol secretion from the zona fasciculata in humans, and cell growth and
aldosterone secretion in the zona glomerulosa. Clearly vasopressin is not the only
factor effective in the adrenal gland (Nussdorfer examines more than 20 candidate
paracrine control molecules (180)) and the redundancy of the system is yet to be
established, but several factors are favourable for vasopressin being involved in this
way.
A crucial element is the route by which molecules secreted by the medulla
are passed to the cortex. There in no recognised blood flow outward from the
medulla to the cortex, and so molecules would have to pass to the outer portions of
the adrenal by diffusion (an example of paracrine action). This delivery of paracrine
controlling elements is aided by the existence of medullary rays. Gallo-Payet and
colleagues consistently observed chromaffin cells in all three layers of rat adrenal
cortex, sometimes reaching to the capsule surrounding the outer layer (181).
Bornstein reported similar observations of chromaffin cells in the cortex of pig, rat,
(182) and human adrenal glands (183). Ultrastructural studies in the rat adrenal
sometimes revealed chromaffin cells releasing secretory products via exocytosis near
adrenocortical cells (184).
Thus, a mechanism for the local delivery of vasopressin to cells, in which the
in vitro effects of vasopressin have been described, seems to be present in the adrenal
gland. Further, Mazzochi describes a theoretical model which rationalises the high
concentrations of vasopressin required to exert an effect in vitro on adrenal (185). In
experiments on the rat adrenal medulla, minimum effective concentration was 10" M
(for future reference, this is equivalent to 10,000 pg AVP/ml) (179), whereas blood
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plasma AVP concentrations are quoted as rarely exceeding 5 xlO"11 M (or 50 pg/ml,
attributed to (186) in (179)). For a molecule to be genuinely considered to be
exerting paracrine control, he stipulates that it must be possible for the adrenal
content of the molecule to generate a local concentration of the molecule equal to the
minimum effective concentration in vitro. He states that the specific gravity of
adrenal gland is 1.039, and the interstitial space in the adrenal gland less than 2-3%
of the total volume. Nussdorfer used this model to make some rough estimations.
Adrenal glands containing molecules with a content of 100 femtomoles/g will
generate a concentration of 10~9 M if 30% of their content is released from cells. He
calculates that AVP concentrations as high as 10"7 M could be generated in the rat
adrenal gland, and 10~6 M in the human (180).
Adrenal glands represent a well-examined model of a potential paracrine role
for vasopressin, and should be used as such when considering novel candidate sites
for vasopressin synthesis and local action.
1.7 Vasopressin in foetal skeletal muscle
It has been proposed that foetal skeletal muscle be added to the list of tissues
that synthesise and locally use biologically active arginine vasopressin. In 1992, a
report was published in Early Human Development, demonstrating high
concentrations (between 10 and 0.04 ng of AVP per g tissue) of apparently specific
vasopressin immunoreactivity in human foetal skeletal muscle (187). The authors
demonstrated this immunoreactivity in a variety of ways. A graphed relationship
between the immunoreactivity from the muscle and gestation age showed that as the
age of the foetus increased, the immunoreactivity per unit tissue weight in the muscle
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decreased. After high performance liquid chromatography (HPLC), the
immunoreactivity was found to dilute in parallel with an extract of pituitary gland
and synthetic AVP treated in a similar manner. Further techniques were used to
locate the immunoreactivity within a molecular weight range. Molecular weight cut
off (MWCO) filters were used to show that the immunoreactivity had a molecular
weight of less than 3kDa. Examples presented showed there was no loss of
immunoreactivity when the extract of foetal muscle was filtered through one or two
MWCO filters and then further extracted using HPLC. The mobility of the
immunoreactivity was shown to be the same as that of synthetic AVP, as radioactive
peaks due to tritiated AVP and immunoreactive peaks from the assay of the extract
had the same retention time. Immunoreactivity was also demonstrated in other AVP
assays using three different antibodies raised against a vasopressin antigen.
The observations of Smith and colleagues fit well with data gathered later in
other laboratories concerning the action of vasopressin on skeletal muscle tissue.
Initial studies designed to investigate the possible effect vasopressin has in the
carbohydrate metabolism of skeletal muscle employed chick embryo myoblasts. The
transients effect of vasopressin on glucose 1,6 - bisphosphate (a strong regulator of
several enzymes involved in carbohydrate metabolism) was examined (188). In pre-
and post-fusion myoblasts, vasopressin was observed to lower levels of glucose
1,6-bisphosphate. The authors drew no conclusions as to whether these changes
were due to a decrease in synthesis of the bisphosphate from glucose 1-phosphate, or
to an increase in the degradation of the molecule itself. However they reasonably
concluded that a peptide affecting the levels of a compound involved in the
carbohydrate metabolism pathway must be influencing conditions or enzymes within
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that pathway. Vasopressin has been shown to produce a glycogenolytic effect on the
liver in the rat and mouse. In the perfused rat liver and in hepatocyte preparations,
vasopressin has been reported to cause both the release of glucose and the
stimulation of glycogen phosphorylase activity (189). This was shown to operate
through a cAMP-independent pathway, implying the involvement of a Vi-type
receptor in the initiation of the glycogenolytic response to vasopressin (190).
Wakelam and colleagues then went on to study the transient response to
vasopressin in the L6 rat myoblast cell line (191). It was shown that vasopressin
stimulated inositol phospholipid breakdown, thereby linking the two strands of
observations in liver and skeletal muscle. No effect on intracellular cAMP
concentrations was seen, establishing both the lack of functional V2-type receptors
and the presence of VI-type receptors, and suggesting further that any effect
vasopressin has on skeletal muscle is mediated via this receptor. On the basis of
these findings Adamo and colleagues were prompted to further study the signal
transduction events and the long term effects of vasopressin on the L6 cell line. L6
cells are immortalised myoblast cells that retain the potential to differentiate into the
mature skeletal muscle phenotype (192). Skeletal muscle fibres are multinucleated
non-mitotic cells, formed from the fusion of progenitor mononucleated myoblasts
(193). When vasopressin was introduced into a culture of L6 myoblasts,
concentration dependent inositol phosphate production was observed (194). In
addition, a biphasic increase of intracellular calcium occurred. The onset of these
effects were seen within 2-3 seconds of the introduction of AVP. Vasopressin was
also able to alter the internal pH of cells. A hypothesis was extended that AVP was
acting as a proliferative factor, and the effect of long-term exposure to AVP was then
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examined (195). Incubation of cells with AVP in the culture medium resulted in an
increase in fusion of myoblasts. L6 cells were seen to fuse without the addition of
AVP but vasopressin increased the rate of this fusion two-fold, and fused cells were
observed to contain higher a number of nuclei. It was later shown that L6 cells could
be held in the non-functional state almost indefinitely with manipulation of the
culture medium (196). The signal transduction pathways activated by vasopressin in
L6 cells was further studied and it was shown that phospholipases C and D were
activated (197, 198). Vasotocin and oxytocin exerted the same effects as vasopressin
on the differentiation of the cells at the same concentration (0.1 pM), but only the
Via receptor was identified through use of selective antagonists of the different
vasopressin receptors.
1.7.1 Foetal development and role of vasopressin
Describing the ontogeny and roles of the neurohypophyseal hormones in the
foetus is hampered by the availability of samples for study and the gestation age of
the foetuses used for study. Much of the data available on the function of the
hormones in the foetus are gathered from the chronically catheterised sheep foetus.
These studies are usually carried out late in the third trimester. Human samples
available for study are not fresh, being gathered from legal therapeutic terminations
with inevitable delay between delivery and sampling, and are not comparable in
terms of stage of gestation, even if the differences in the development of sheep and
humans can be overcome. In this section, therefore, it should be borne in mind that
referring to the foetus is usually a reference to observations made on the third
trimester foetus.
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The anatomical components of the hypothalamo-neurohypophyseal system
are established and developing by the 7th week of gestation in the human (199).
Reports vary, but it seems that the demonstration of vasopressor activity is not
possible before week 10 (21). Vasopressin has been detected in human foetal
posterior pituitaries as early as the 11th week of gestation (200). In early gestation
foetuses a high vasopressin to oxytocin ratio is observed. This is due to a time
difference between the appearance of oxytocin and vasopressin in the posterior
pituitary - vasopressin is detectable 3-4 weeks before oxytocin (201). In the adult
human posterior pituitary gland, vasopressin, oxytocin and their respective
neurophysins are present in roughly equal proportions (202), but this ratio is not seen
until at least the neonatal period (21). However, the ratio of the individual
neurophysins remains relatively constant despite a thousand-fold increase in tissue
stores in the ensuing 3-4 months. Thus, the changes in the ratio of vasopressin to
oxytocin are not due to relative changes in rates of de novo synthesis, and instead
have been explained by the later maturation of processing machinery in the oxytocin
producing cells (201).
Vasopressin seems to be able to play a role in adaptation to intrauterine
stress. Basal and raised circulating levels of vasopressin are due to foetal release
because vasopressin and oxytocin do not cross either ovine or human placenta (203).
Although basal levels of either hormone have not been established in humans,
vasopressin has been measured in ovine foetal blood at mid-pregnancy (204). Basal
maternal levels in the sheep are similar to non-pregnant ewes and human adults, as
are foetal vasopressin levels in sheep.
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The internal environment of the foetus is ostensibly controlled by the mother.
However, vasopressin is capable of affecting conditions in foetal physiology.
Elevated levels of vasopressin affect the foetal renal, lung and cardiovascular
systems. By mid-term, the foetus is capable of increasing circulating levels of
vasopressin in response to osmotic stimuli (205), hypoxia as a result of maternal
hypoxia (206), haemorrhage (207), and dehydration of maternal origin (204). The
foetal response to hypoxia is proportional to the degree and duration of the episode
(208). Foetal lung fluid production is diminished by vasopressin infusion (209). In
the short term, therefore, vasopressin can diminish water loss through the foetal lung.
Water loss can also be controlled by the foetal kidney, but the kidney is not fully
functional. The response to stimuli like these matures with increasing gestation age
so that only by birth are secretory responses mediated by osmolar and volume
receptors similar to those in the adult. This maturation is demonstrated by the
antidiuretic capabilities of the foetus. Under basal conditions, foetal urine osmolality
is significantly lower than plasma osmolality. Even during infusion of exogenous
vasopressin, maximal foetal urine osmolality rarely exceeds plasma osmolality.
Cardiovascular responses to vasopressin are also seen. There is a
redistribution of the cardiac output to spare the placental, myocardial and cerebral
circulation (210).
Increased vasopressin secretion elevates foetal blood pressure and leads to
bradycardia. Parturition is also associated with increased ovine foetal vasopressin at
a time when there is no concomitant maternal secretion. This is undoubtedly a
response to the mild hypoxia associated with labour, because in caesarean section
deliveries cord blood vasopressin levels are only minimally elevated at birth.
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1.8 Proposal of a model for the action of vasopressin in foetal
human skeletal muscle
It would seem obvious that a circulating concentration of vasopressin
necessary to mimic the effects on skeletal muscle observed in vitro could have
profound effects on the normal physiology of the foetus, and so the remaining option
is the local synthesis of smaller amounts of vasopressin that would generate the
required concentrations to exert an effect with a paracrine or autocrine action. A
model of vasopressin action on foetal skeletal muscle is therefore proposed, whereby
vasopressin is present in the high levels reported in early gestation in order to
promote the fusion of myoblasts, generating multinucleated myofibrils, and thus
promote cell growth and maturation to form functional units ofmuscle. As gestation
progresses, the requirement for vasopressin-induced fusion is lessened, as the ratio of
myoblasts to mature muscle cells progressively lowers, and so production of
vasopressin is lowered. This could happen in one of two ways. If the muscle cells
themselves produce the vasopressin (an autocrine action), then the simple effect of
the lowering of the number of cells in the muscle will result in this lowering of
concentration. If, however, it is an associated cell type that produces the vasopressin
(a paracrine action), then the rate of synthesis and release of vasopressin would need
to be down-regulated in some manner.
1:9 Conclusion
The following chapters describe the experiments carried out to investigate the
possibility that vasopressin is found at physiologically significant levels in foetal
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human skeletal muscle. Employing the criteria set out in Section 1.6 and using the
example of the adrenals glands, it is proposed that the synthesis of vasopressin in
skeletal foetal muscle should be examined in a stepwise manner, in order to
extrapolate the observations in the rat myoblast L6 cell line to those of human foetal
muscle.
Initially, confirmation of the immunoreactivity in human foetal muscle
should be carried out using radioimmunoassay. The localisation of the source of the
immunoreactivity should be investigated, using immunohistochemistry or in situ
histochemistry. Generally, it should be established if it is possible to isolate a viable
vasopressin mRNA from the muscle tissue, using either RT-PCR or Northern
blotting. The presence of enzymes involved in the maturation of translated gene
should be demonstrated to show that the preprohormone can be processed to give an
active final product.
A vasopressin receptor should also be localised in order to establish that the
vasopressin signal can be transduced. Presumably, content of the receptor will also
diminish with time, but as the action of vasopressin on mature skeletal muscle has
been described (188), this is not certain. The concentration of the receptor on the
surface of the myoblast could be found using membrane preparations, and a mRNA
for the receptor should be sought using either RT-PCR, Northern blotting, or in situ
hybridisation. The messenger cascades stimulated by vasopressin binding should also
be investigated on primary cultures of human myoblast cells.
The following chapters describe the experiments carried out in an effort to
reproduce the observations of Smith et al that high levels of vasopressin were found
in the skeletal muscle of human foetuses (187). Additionally, the presence of the
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Vla-vasopressin receptor was examined using Western blotting and
immunohistochemistry.
Chapter 2
Materials and Experimental Procedures
2.1 Samples used in studies
2.1.1 Samples used in experiments for the extraction, gel filtration, and
radioimmunoassay of vasopressin
Adult rabbit skeletal muscle was taken from an adult female New Zealand
White rabbit, kindly donated by the Faculty of Medicine Animal Facility (FMAF,
Faculty of Medicine, University of Edinburgh, UK). The rabbit was sacrificed by
lethal injection of anaesthetic. The quadriceps muscle was immediately dissected out,
divided into portions, snap frozen, [MFLijand stored at -70°C until used.
Adult rat adrenal glands were taken from adult female Sprague Dawley rats,
kindly donated by the FMAF. The rats were sacrificed by suffocation using CO2 gas,
and after transportation, the adrenal glands were dissected out, weighed and snap
frozen.
Foetal human muscle, liver, pituitary, and adrenal glands representing
different stages of mid-trimester development were taken from therapeutic
terminations carried out at the Simpson's Memorial Flospital, Edinburgh, UK.
Tissues were obtained as quickly as possible after the procedure. Ethical consent was
sought and received from all donors at the time of the procedure, in accordance with
a study protocol approved by the Paediatrics & Reproductive Medicine Research
Ethics Sub-Committee for the Lothian Health Board (Protocol reference
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1702/94/6/6). All foetuses were anonymously donated and processed in accordance
with guidelines set out in the Polkinghorne Report (211). Only those foetuses
without obvious external malformation or pathology were released for study.
An estimated gestation age was supplied with each foetus, but it is not known
how definitive this estimate was. Gestation ages were generally assigned as being a
whole or half a week, for example, 15 weeks, 15+ weeks, 16 weeks. This gave rise to
concerns regarding the accuracy of gestation age and any attempts to correlate this
age with the actual development of the foetus. Accordingly, the foetus was weighed,
and the foot length measured using the directions of Hern (212). The foot was placed
flat on a ruler, and the foot length measured from the back of the heel to the tip of the
longest toe (usually the second toe). Both feet were measured, and the mean noted as
the foot length. Foot length has been shown to be a reliable indicator of gestation age
(first defined by Streeter in 1920(213)), and this parameter can be used as a marker
of foetal development (212, 214, 215).
Foetal human quadriceps muscle, adrenal glands, and the pituitary gland as a
whole (the middle cranial fossa was cut away from the base of the skull) were
dissected from the foetus, snap frozen and stored at -70°C.
2.1.2 Samples used in immunoblotting experiments
Samples of adult rabbit and foetal human quadriceps muscle (obtained as
described above) and foetal human liver were defrosted, weighed, and then refrozen.
These samples were then freeze dried and stored at -20°C prior to transportation at
room temperature.
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5x 107 MCF-7 cells for a positive control preparation, and an adult human
liver positive control sample were kindly donated by Dr William North (Department
ofPhysiology, Dartmouth Medical School, Dartmouth College, Lebanon, NH, USA).
2.1.3 Samples used in immunohistochemistry experiments
Foetal human skeletal muscle, pituitary and adrenal glands (dissected from
foetuses as described above) were immediately fixed in 4% phosphate buffered
formalin solution. Tissues were subsequently processed by gradual removal of the
fixative and embedded in paraffin wax by staff in the Pathology Department at the
Royal Hospital for Sick Children, Edinburgh, UK.
Adrenal glands were taken from adult female Long-Evans rats immediately
after sacrifice by decapitation. They were fixed in 10% phosphate buffered formalin.
Fixative was removed and the tissues were embedded in paraffin wax by staff in the
Histotechnology Section of the Department of Anatomical Pathology at the
Dartmouth Hitchcock Medical Center (DHMC), Lebanon, NH, USA.
Adult human hypothalamus and adrenal gland tissue were cut from control
blocks of normal hypothalamus and adrenal gland tissue kindly provided by the
Department of Anatomical Pathology at the Dartmouth Hitchcock Medical Center. In
order to protect patient confidentiality, information as to the source of the tissues was
not made available.
Slides were stained using hemotoxylin and eosin using facilities in the
Histotechnology Section of the Department of Anatomical Pathology at DHMC.
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2.2 Materials
2.2.1 Materials used in the extraction and radioimmunoassay of vasopressin
All solutions were prepared using double distilled water.
Tissues were thoroughly homogenised in 1M acetic acid (from glacial acetic
acid, HPLC grade, Fisher Scientific UK Ltd.) using a Kinematica Polytron
homogeniser (Brinkmann Instruments Inc., Westbury, NY, USA). Homogenisations
were carried out in 50ml conical tubes (Sarstedt Ltd., Beaumont Leys, Leicestershire,
UK).
All assays and binding experiments were carried out in LP2 tubes (Sarstedt
Ltd.). Radioimmunoassays were counted using a Cobra II Autogamma counter
(Packard Bioscience Ltd., Berkshire, UK).
2.2.1.1 Buffers and solutions
Assay buffer was based on 0.05M Tris-hydrochloric acid (Tris-HCl) buffer.
Tris (SigmaUltra grade, Sigma-Aldrich Company Ltd., Poole, Dorset, UK) was
weighed out and the pH adjusted to 7.2 using 5M (5N) hydrochloric acid (Standard
Volumetric Solution, Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK).
0.3% (w/v) bovine serum albumin (BSA, RIA grade fraction V, Sigma-Aldrich
Company Ltd.) was added. 0.1% (v/v) Triton X-100 and 0.05% (w/v) sodium azide
(both SigmaUltra grade, Sigma-Aldrich Company Ltd.) were also added. The buffer
was prepared in batches of 1 litre and stored at 4°C. Primary antibodies, AVP
standard, and radio-labelled AVP and samples were all diluted to appropriate
concentrations in this buffer.
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Adjustment of the pH of extracted samples containing 1M acetic acid was
carried out using 2M Tris (SigmaUltra grade, Sigma-Aldrich Company Ltd.). pH was
checked using a pH meter (Accumet pH Meter 915, Fisher Scientific UK Ltd.). Tris
was added until the pH of a sample reached 7.2.
Bound and unbound portions of the assay were separated by the total
precipitation of the primary antibody using a second antibody directed against the
species in which the primary antibody was raised. Precipitation of an antibody-
antigen complex only occurs at high concentrations of the antibody and so is not seen
in other parts of the assay. Precipitation is brought about by adding normal serum
from the primary antibody species to provide the required high concentration of
antibody-antigen complex. Precipitation is further enhanced by the use of
polyethylene glycol (PEG) which absorbs excess water (216). Second antibody
solution sufficient for 200 tubes was made using 24ml of assay buffer, 24ml of an
8% (w/v) PEG 8000 solution (SigmaUltra grade, Sigma-Aldrich Company Ltd.), 2ml
of neat donkey anti-rabbit serum for assays using tgl antiserum (or anti-sheep for
assays using the s278 antiserum) and 200pl normal rabbit serum for the tgl assay (or
sheep serum for the s278 assay). These sera were all supplied specifically for the
development of, and use in, radioimmunoassays by the Scottish Antibody Production
Unit (SAPU, Lanarkshire, UK). Precipitated bound tracer was sedimented by
centrifugation using a Jouan CR 422 centrifuge (Jouan Ltd., Ilkeston, Derbyshire,
UK).
Storage buffer was used to dilute and store AVP standard and l2"T-labelled
AVP and was made when required. This buffer consisted of 0.2% (v/v) acetic acid
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(Fisher Scientific UK Ltd.) and 0.2% (w/v) BSA (Sigma-Aldrich Company Ltd.) in
distilled water.
2.2.1.2 Radio-labelledpeptides, peptide standards and analogues
Iodinated (123I-labelled) AVP (Amersham Pharmacia Biotech UK Ltd.)was
used as the tracer in all radioimmunoassays. The half life of 125I is approximately
sixty days, and tracer was replaced within this period. No change in the stability of
the tracer was apparent in this time. Each consignment was divided into aliquots,
each of which provided sufficient radioactivity for approximately 1000 assay tubes
(5000 counts per minute (cpm) per tube) in 50pl. Unused tracer was stored at 4°C
and used within four days. Disposal of tracer was carried out according to local
regulations.
Peptide labelled with a radioactive isotope was also used to evaluate
extraction efficiency of the procedure and to standardise elution of peptide in gel
filtration chromatography experiments. AVP labelled with tritium ( H-AVP) was
purchased in 50pCi batches (Amersham Pharmacia Biotech UK Ltd.). Samples
containing radioactive peptide were counted in quadruplicate. Aliquots were mixed
with Picofluor 40 liquid scintillation cocktail (Packard Bioscience Ltd.) and
disintegrations per minute (dpm) were counted for a two minute period using a
Tricarb 1900 CA liquid scintillation analyser (Packard Bioscience Ltd.).
Synthetic AVP was used for the generation of standard curves in all
experiments, and in experiments where AVP was added as a supplement (BACHEM
(UK) Ltd., St. Elelens, Merseyside, UK). Aliquots of lOOng/ml concentration were
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prepared in storage buffer and stored at -20°C. A new aliquot was used every time a
standard curve was set up.
The 1st International Standard for Vasopressin for Bioassay (National
Institute for Biological Standards and Control, London, UK) was used in the
radioimmunoassay as the standard reference material, and for quality control
samples. An ampoule was broken and dissolved using storage buffer to give aliquots
of lpg/ml, which were stored at -70°C. These aliquots were diluted in assay buffer
to make three different concentrations of reference standard which were stored at
-70°C and used in every assay. Two different sets of reference pools were created;
one for the tgl and one for the s278 assay. The concentrations were chosen so as to
provide a high (20% binding) medium (40% binding) and low (70% binding) dose
when assayed as a sample in an assay. Quality control pools were changed every
three months.
The specificities of the tgl and s278 antisera were tested using lysine
vasopressin, oxytocin and vasotocin (BACHEM (UK) Ltd.), structurally similar
peptides that are also found in mammals.
2.2.1.3 Antibodies used as binders in the radioimmunoassay
tgl is a polyclonal antiserum. It was raised in rabbits using bovine
thyroglobulin conjugated arginine vasopressin (AVP). Use of this antibody has been
described in several publications (187, 217-219).
s278 is a polyclonal antiserum raised in a sheep. It was raised at the Scottish
Antibody Production Unit (SAPU, Lanarkshire, UK) facility using bovine
thyroglobulin conjugated AVP. Information concerning the number and timing of the
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immunisation injections was not available. Serum was pooled from several bleeds,
and stored at -20°C until used. Use and partial characterisation of the s278 antiserum
has been described before (187, 217, 218).
2.2.1.4 Materials used in solidphase extraction
Isolute End Capped octylsilyl-sylica (C8 silica) cartridges were used for the
solid phase extraction of vasopressin from extracted tissues (International Sorbent
Technology, Hengoed, Mid-Glamorgan, UK). Each cartridge contains 500mg of
adsorbent, with a 10ml reservoir for addition of solutions and samples. Solutions and
samples were drawn through the adsorbent using a Varian Vac-Elut 10 vacuum
manifold (Varian Inc., Walton-on-Thames, Surrey, UK). The vacuum pressure was
changed at the different steps to cause different flow rates, but pressures were not
quantified. Elutates of interest were dried under vacuum using a Gryovap centrifuge
(Philip Harris Scientific, Ashby de la Zouch, Leicestershire, UK).
Prior to use, the cartridge adsorbent was stripped with methanol (Certified
HPLC grade, Fisher Scientific UK Ltd.) then washed with an 80% aqueous
acetonitrile (ACN, Certified HPLC grade, Fisher Scientific UK Ltd.) solution
containing 0.2% trifluoroacetic acid (v/v) (TFA, HPLC grade, Fisher Scientific UK
Ltd.). ACN was washed out using aqueous 0.2% TFA solution. Samples were loaded
to dryness, and the retained sample was washed (to remove weakly bound
impurities) with aqueous 0.2% TFA solution. Samples were eluted with 80%
aqueous ACN containing 0.2%TFA. The cartridges were regenerated by washes with
methanol, followed by 80% aqueous ACN solution containing 0.2%TFA, and finally
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0.2% aqueous TFA solution. The cartridges could be used 3 times before being
discarded, with no loss of extraction efficiency (data not shown).
2.2.2 Additional Materials used in gel filtration experiments
Gel filtration chromatography was carried out using Sephadex G-25 gel (Fine
grade, Sigma-Aldrich Company Ltd.). Weighed quantities (47g) of gel were swollen
overnight in 250ml of 0.05M Tris-HCl (pFI 7.2) buffer at 4°C. Swollen resin was
packed into a 70cm (length) x 16mm (internal diameter) chromatography column
('C' type, Amersham Pharmacia Biotech UK Ltd.) under gravity flow. All samples
were eluted in 0.05M Tris-HCl (pH 7.2) buffer and experiments were carried out at
4°C. The void (or exclusion) volumes were established using Blue Dextran, a
coloured marker with an average molecular weight of 2x106 Da (Sigma-Aldrich
Company Ltd.), and was found to be approximately 44ml. Fractions were collected
using a Gilson 201 fraction collector (Anachem Ltd., Luton, Bedfordshire, UK).
Fractions from gel filtration experiments were sometimes pooled and
concentrated using solid phase extraction. The resulting samples were dissolved in
assay buffer and centrifuge filtered with a molecular weight cut off device that had a
cut off weight of lOkDa (Microcon YM-10, Millipore (U.K.) Limited, Watford,
Hertfordshire, UK).
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2.2.3 Additional materials used in immunoblotting experiments
2.2.3.1 Lysis buffer and other solutions and buffers used in electrophoresis,
transfer, and Western blot analysis
Weighed portions of freeze dried samples were extracted for protein in one of
two ways. Some samples were extracted using TRIzol reagent (Life Technologies,
Rockville, MD, USA), a monophasic solution of phenol and guanidine
isothiocyanate that can be used to isolate total RNA, DNA, and protein from the
same sample. Other samples were extracted for protein in lysis buffer. The lysis
buffer was 0.01M ammonium chloride solution buffered with 0.05M Tris-HCl
(pH7.5), and also contained proteolytic enzyme inhibitors 0.2U/ml aprotinin, and
InM phenylmethylsulfonylfluoride (PMSF, both Sigma-Aldrich Company Ltd.)
(220). This buffer has been used in the lysis of cultured cells for Western blot
analysis of vasopressin receptors (221).
Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS - PAGE)
was carried out using standard electrophoresis running buffer containing Tris,
glycine and SDS (purchased as a premixed lOx buffer, Bio-Rad Laboratories,
Hercules, CA, USA) (222).
Proteins were transferred from gel to membrane using a standard transfer
buffer containing 15% methanol (Certified HPLC grade, Fisher Scientific,
Pittsburgh, PA, USA), Tris and glycine (pH 8.3, made according to instructions in
(222)).
Between additions of antibodies, membranes were washed in standard
phosphate buffered saline solution (PBS, pH 7.3, made according to instructions in
(222)) containing 0.1% (v/v) polyoxyethylenesorbitan monolaurate (Tween 20,
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Electrophoresis grade, Sigma-Aldrich Company Ltd.)- Antibodies were also diluted
and incubated with the membranes in this buffer with 5% (w/v) BSA (RIA grade
fraction V, Sigma-Aldrich Company Ltd.) added.
2.2.3.2 Antibodies used in immunoblotting analysis
Antibody used in the detection of the Via receptor subtype (vivian) was
generated using a peptide conjugated to bovine thyroglobulin. The peptide used was
a sequence unique to the human form of the receptor, and comprised part of the
second putative extracellular loop and a portion of the transmembrane region 5 of the
receptor structure (221). The antibody had previously been used in a
radioimmunoassay for the receptor using the radio-iodinated peptide, and in Western
blot analysis of vasopressin receptors in cell lines (221). The rabbit antiserum had
previously been fractionated (using Immunopure Immobolized Protein-A, Pierce,
described in (221), and the IgG2b fraction was used at a concentration of 10pg/ml.
Foetal muscle samples were normalised for content of relevant protein using
a mouse monoclonal antibody directed against human B-dystroglycan (Novocastra
Laboratories Ltd., Newcastle upon Tyne, UK). This protein is a member of a group
of proteins known as dystrophin associated glycoproteins (DAGs), and is thought to
be involved in the attachment of dystrophin to muscle membranes (223). It has been
used in the study of the developmental expression ofmembrane cytoskeletal proteins
in human skeletal muscle (224).
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2.2.3.3 General materials used in immunoblotting experiments
Samples extracted using TRIzol reagent were homogenised using a
Kinematica Polytron homogeniser (Brinkmann Instruments Inc.).
Samples were homogenised in lysis buffer using a sonicator (Model W-380,
Heat Systems - Ultrasonics, Inc., Farmingdale, NY, USA). Homogenates were spun
at 12,000g for 10 minutes using an Eppendorf 5415C centrifuge (Eppendorf
Scientific, Inc., Westbury, N.Y, USA). Supernatants were decanted and stored at -
20°C until used.
Protein content of the samples was estimated using a protein assay kit (BCA-
200 Protein Assay Kit, Pierce, Rockford, IL, USA). Prior to electrophoresis, samples
were mixed with 2x sample buffer containing Tris, glycerol, SDS, and bromophenol
blue (Laemmli Sample Buffer, Bio-Rad Laboratories, Hercules, CA, USA) with, or
without, 0.05M dithiothreitol (DTT, electrophoresis grade, Sigma-Aldrich Company
Ltd.). Pre-stained protein standard markers were added to a separate well for the
purpose of estimating molecular weights of identified proteins (Kaleidoscope Pre-
stained Standards, Bio-Rad Laboratories, Hercules, CA, USA).
SDS-PAGE and electro-blot transfer was carried out using Biorad Mini-
Protean 3 cell and mini-Trans Blot apparatus (Model 1000/500 powerpack, Bio-Rad
Laboratories, Hercules, CA, USA). 12% polyacrylamide Tris-SDS gels were
prepared according to the method of Laemmli (222). Separated proteins were
transferred to PVDF membrane (Immobilon-P transfer membrane, Millipore
Corporation, Bedford, MA, USA). Membranes were dried using a gel dryer (Model
583, Bio-Rad Laboratories, Hercules, CA, USA).
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Binding of vivian to target antigen was detected using a horse radish
peroxidase (HRP) conjugated goat anti-rabbit IgG (Premium Quality, Human serum
adsorbed, Gibco BR1 Life Technologies, Rockville, MD, USA). Binding of the anti-
beta-dystroglycan antibody was detected using a horse radish peroxidase (HRP)
conjugated goat anti-mouse IgG (ImmunoPure Goat Anti-Mouse IgG, Pierce).
Immunoreactive proteins were visualised by incubating the membrane in
chemiluminescent substrate (Lumi-Light Western Blotting Substrate, Roche
Diagnostics Corporation, Indianapolis, IN, USA), and photographic film (Super RX
X-ray film, Fuji Film USA) was exposed to the membrane in a darkroom. Films were
developed using a Kodak RP -Omat processor (Model M7B, Eastman Kodak Co.,
Rochester, NY, USA).
2.2.4 Additional materials used in immunohistochemistry experiments
2.2.4.1 Tissue sectioning
Paraffin embedded tissues were cut into 5 pm sections using a microtome
(RS4800 model, Surgipath Medical Industries Inc., Richmond, IL, USA), laid out in
a water bath set at 37°C (tissue floatation bath, Surgipath Medical Industries Inc.),
and transferred to microscope slides that had been previously coated with a tissue
section adhesive according to manufacturers instructions (Biobond, BBInternational,
Cardiff, UK). The sections were air dried at room temperature for at least 12 hours
before use.
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2.2.4.2 Immunohistochemistry buffer and other solutions
Immunohistochemistry buffer was a 0.05M sodium phosphate buffered
(pH7.5, Sigma-Aldrich Company Ltd.) 0.9% (w/v) saline (sodium chloride, Sigma-
Aldrich Company Ltd.) solution. The buffer also contained 0.25% (w/v) Triton X-
100 (Sigma-Aldrich Company Ltd.). The buffer was used as a wash between
applications of reagents and used to dilute antibodies and normal sera.
Paraffin was removed from tissue sections using xylene (Histological grade,
Fisher Scientific) and the tissues rehydrated using decreasing concentrations of
alcohol (diluted from absolute ethyl alcohol, Aaper Alcohol, Shelbyville, Kentucky,
USA). Endogenous peroxidase activity, responsible for background staining where
enzymes were active, was blocked using 0.3% hydrogen peroxide (from 30% stock,
certified ACS grade, Fisher Scientific) in methanol (Fisher Scientific).
Antigen retrieval was carried out either by heating the slides in a Samsung
MT4600 microwave oven using Antigen Unmasking Solution (Vector Laboratories
Inc., Burlingame, California, USA), or by incuabtion with trypsin (DAKO
Corporation, Carpinteria, CA, USA). Trypsin was removed by washing with 95%
ethanol (Aaper Alcohol, Shelbyville, Kentucky, USA)
Normal serums were used as negative controls. Binding of the primary
antibody was demonstrated using Universal Biotinylated Antibody (a mixture of
biotinylated anti-rabbit and anti-mouse antibodies, Vector Laboratories Inc.). Avidin
Biotin Complex (ABC kit) was applied, and colour was developed using a 3'3'-
diaminobenzidine (DAB) kit. Slides were counter stained with hemotoxylin solution.
(All the above were purchased from Vector Laboratories Inc.)
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Immunohistochemistry experiments were carried out using coverplates
(Shandon Inc., Pittsburgh, Pennsylvania, USA). These are moulded covers that
create a uniform channel over the tissue section. Use of these coverplates allows
lower volumes of reagents to be used and provide control over addition of set
volumes of solutions to the slide surface. Additionally, the coverplates are designed
to keep a constant layer of solution over the tissue section, preventing the slide from
drying out at any stage in the procedure.
2.2.4.3 Antibodies used in immunohistochemistry experiments
Vimentin was detected using a mouse monoclonal antibody (BioGenex
Laboratories Inc., San Ramon, CA, USA). Vimentin is an intermediate filament that
has been shown to be present in foetal skeletal muscle until 36 weeks gestation
(225). It has also been used as a marker for certain tumour types (226).
Vasopressin was detected using a rabbit polyclonal antiserum (gonzo). The
antibody was generated to vasopressin coupled to bovine thyroglobulin and has a
cross reactivity of less than 0.01% with oxytocin (227). It has been used in the
immunohistochemical investigation of vasopressin expression in gastrointestinal
cells of rats (227). The antibody was used as a dilution of the neat serum without
purification.
vivian, an anti-vasopressin Via receptor antiserum (described in Section
2.2.3.2) was also used.
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2.3 Experimental procedures
Statistical analysis was carried out using Instat 2.03 (Graph Pad Software
Inc., SanDiego, CA USA), a statistical package for the Macintosh. Lines of linear
regression and curve fits on graphs were imposed by algorithms resident in the
software of Microsoft Excel 98 (Microsoft Corporation).
2.3.1 Homogenisation and Extraction
Tissues were thoroughly homogenised in hot molar acetic acid using a
Polytron homogeniser. Elomogenisations were carried out in 50ml conical tubes.
Samples were then boiled for ten minutes and homogenised again. Homogenates
were centrifuged at 12,000g for 45 minutes at room temperature.
2.3.2 Vasopressin Radioimmunoassay
2.3.2.1 Basicprotocol
Both the tgl and s278 assays were set up in the same manner. Four different
types of tubes were set up: Total Counts tubes, Non-Specific Binding tubes, Bo tubes,
and Sample or Standard tubes. All measurements were carried out in triplicate. The
assay is summarised in Figure 2.1. Standard curves were made appropriate to the
antiserum used in the assay, tgl assay standard curves were set up over a range of
100-lpg/ml (l-100pM), and s278 assay standard curves covered a range of 7-
2000pg/ml (7-2000pM).
On day 1, nothing was added to Total Counts tubes. lOOpl of assay buffer
was added to Non-Specific Binding tubes. Primary antibody was added to B0 tubes in
50pl, and together with 50pl of assay buffer. Sample tubes had 50pl of sample (or
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AVP standard) and 50pl of primary antibody added to them. The tubes were mixed
by vortexing and incubated overnight at 4°C.
On day 2, 125I-AVP (5000 counts per tube) was added to all tubes. All tubes
were mixed by vortexing, then incubated overnight at 4°C.
On day 3, 250pi of second antibody/PEG mixture was added to all tubes
except the Total Counts tubes. Tubes in which second antibody/PEG mixture had
been added were incubated for 1 hour at 4°C, and then centrifuged for 20 minutes at
2,500g at 4°C. The supernatant (containing the unbound fraction) were aspirated and
discarded from each tube, leaving only the pellet (containing the bound fraction) in
the tube. All tubes were counted for 5 minutes. Assays were counted using the Cobra
II Autogamma counter. The built-in computer constructed standard curves using a 4-
parameter logistic fit, and values for the concentration of vasopressin in samples
were extrapolated within the same program.
2.3.3 Solid phase extraction
The extraction protocol is similar to that preferred by Van de Heijning and
colleagues (228). Prior to use, the cartridge was stripped with a reservoir volume
(10ml) of 100% methanol, then washed with 4.5ml of an 80% aqueous ACN
containing 0.2% aqueous TFA solution. This wash 'activated' the cartridge for
sample loading. Two 10ml volumes of 0.2% aqueous TFA solution were washed
through the resin to remove ACN. Over these first steps it was found to be
imperative that the adsorbent did not dry out.
Samples that did not contain acid were supplemented with 0.2% TFA





















Incubate overnight at 4°C
125I-AVP (5000
counts per tube)
Add 50pl Add 50pl Add 50pl Add 50pl
DAY 3
Incubate overnight at 4°C
Second antibody - Add 250pl Add 250pl Add 250pl
/PEG mixture
Incubate for 1 hour at 4°C
Centrifuge tubes (except total counts) at 2500g for 20
minutes at 4°C
Aspirate and discard unbound portion (supernatant).
Count all tubes for 5 minutes
FIGURE 2.1 Basic protocol for vasopressin radioimmunoassay
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was applied so that each sample was loaded at a rate of less than 1ml every two
minutes, to ensure sufficient exposure of the sample to the adsorbent. Samples were
loaded to dryness (until all solution had passed entirely through the adsorbent). Two
10ml volumes of 0.2% aqueous TFA were passed through the cartridge, again to
dryness. (This step was to wash away any weakly bound non-specific proteins.)
The sample was then eluted with 4.5ml of the 80% aqueous ACN solution
containing 0.2% TFA, with collection over a ten minute period. The resin was then
regenerated by a wash with one cartridge reservoir full of 100% methanol followed
by a reservoir volume of the 80% aqueous ACN solution containing 0.2% TFA, and
finally two reservoirs volumes of 0.2% aqueous TFA solution. After vacuum drying
of the eluted sample, assay buffer was added and samples were left to stand at room
temperature for 1 hour prior to the assay. Samples extracted using this method were
either assayed using one of the vasopressin radioimmunoassays or counted for
radioactivity.
2.3.4 Gel filtration chromatography
Gel filtration was employed to establish physical elution properties of
immunoreactivity observed in some samples.
Samples were added to prepared Sephadex G-25 columns, and were eluted
with a flow rate of approximately lml/min by gravity fed flow. All samples were
eluted in 0.05M Tris-HCl (pH 7.2) buffer. Eluant was collected in 1ml fractions.
Fractions were immediately assayed, either for vasopressin by radioimmunoassay, or
by counting of radioactive isotope in aliquots.
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Concentrated fractions were centrifuged in molecular weight cut-off filters as
recommended by the manufacturers.
2.3.5 SDS-PAGE and immunoblotting experiments
Foetal muscle and liver, samples were extracted for protein using TRIzol
reagent. This is a three step extraction in which DNA and RNA are isolated first. The
extraction was carried out according to the supplied instructions, and the DNA and
RNA fractions discarded.
Weighed portions of the freeze dried muscle samples were added to lysis
buffer and left for one hour at 4°C. These samples were then homogenised by
sonication for fifteen 2 second bursts at 30% of full power. MCF-7 cells were
sonicated without any prior period of standing. Homogenates were then spun for ten
minutes at 12,000g at 4°C, and supernatants were decanted and stored at -20°C until
used.
Samples extracted using TRIzol reagent were normalised for protein using
absorbance at 280nm. Samples extracted in lysis buffer were assayed for protein
according to the manufacturers instructions. After protein assay, samples were mixed
1:1 with Laemmli sample buffer and heated at 70°C for ten minutes. 25pg of total
protein were added to individual wells. Samples were separated by electrophoresis
for 2 hours at 75V.
Separated proteins were transferred to Immobilon-P transfer membrane using
Biorad electroblotting apparatus in transfer buffer. Transfers were carried out
overnight at 20V at 4°C. After removal from the electroblotting apparatus,
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membranes were thoroughly washed in double distilled water. Blocking was
achieved by completely drying the membranes for 30 minutes at 50°C.
Primary antibodies were applied to the membranes by overnight incubation at
4°C. All antibodies were diluted in Western blotting buffer containing 5% BSA.
After this, membranes were washed in Western blotting buffer for 15 minutes and
three 5 minutes periods with fresh changes of buffer. Goat anti-rabbit second
antibody was diluted to 1:20,000 (v/v) with Western blotting buffer containing 5%
BSA, and membranes were incubated in this solution for 1 hour at room temperature.
Second antibody solution was removed and the membrane was washed for 15
minutes and three periods of 5 minutes with fresh changes of buffer.
Immunoreactive proteins were visualised using chemiluminescence. The
membrane was incubated in Lumi-Light Western Blotting substrate (Boehringer
Mannheim) for 3 minutes. The membrane was then exposed to x-ray film.
A negative control experiment was carried out by repeating the above with
the omission of primary antibody.
2.3.6 Immunohistochemistry
2.3.6.1 General procedure
After melting the paraffin wax by heating the slides for twenty minutes at
55°C, paraffin wax was removed by immersion in four changes of xylene for five
minutes. Xylene was removed by washing in 100% ethanol and tissues were
rehydrated by five minutes incubations in 95% ethanol (once), 90% ethanol (twice)
and 70% ethanol (twice). The slides were then immersed for five minutes under
running tap water.
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Antigen unmasking was achieved either by microwave antigen retrieval, or
trypsin digestion. Non-enzymatic methods of antigen unmasking have been shown to
sometimes uncover antigens on formalin fixed paraffin embedded tissue sections not
revealed by enzymatic treatment (229, 230).
Microwave antigen unmasking was performed after the tap water wash by
heating the slides in a citrate solution (750pl of antigen unmasking solution in 80ml
distilled water). Slides were heated for two five minute periods (1150W power -
oven was set to power rating 3) or until the solution had just started to boil. After
incubating the slides for twenty minutes at room temperature, slides were washed for
five minutes in running tap water.
Endogenous peroxidase activity was then blocked by a twenty minute
incubation in a 0.9% hydrogen peroxide solution in 100% methanol.
After being rinsed in tap water, the slides were loaded onto coverplates whilst
immersed in distilled water and placed in a coverplate rack. The slides were rinsed
with three fillings of the coverplate reservoirs with IHC buffer.
Where appropriate (when microwave antigen retrieval had not been carried
out), 200pl of a lmg/ml aqueous trypsin solution was added to the slides and
incubated at room temperature for twenty minutes. The trypsin was removed by
adding 1ml of 95% alcohol. The alcohol was then washed away by filling the
reservoir three times with IHC buffer.
Non-specific binding of antibody was blocked by incubation for twenty
minutes with 5% (v/v) normal goat serum in IHC buffer. After a light rinse (1ml of
IHC buffer added to reservoir), the primary antibody (diluted to the correct ratio in a
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10% (v/v) solution of normal goat serum) was added in a 200pl aliquot and
incubated overnight at 4°C.
Slides were washed with IHC buffer (two fills of the coverplate reservoir)
and the slides incubated for thirty minutes at room temperature with biotinylated
second antibody. After washing (two fills of IHC buffer), the slides were incubated
with an avidin-biotin enzyme complex (ABC kit) for thirty minutes at room
temperature. Colour was developed after washing away excess ABC, by incubating
with 200pl of the DAB kit for three to six minutes. DAB was washed away with
distilled water. The slides were counter stained with haemotoxylin for 1 minute.
Excess haemotoxylin was washed away with distilled water. Slides were removed
from the coverplates, dehydrated through increasing concentrations of alcohol,
dipped in xylene for three minutes and coverslipped.
2.3.6.2 Treatment ofspecific tissues
Hypothalamus and posterior pituitary tissue section antigens were retrieved
by treatment with trypsin. They were incubated with negative control (normal rabbit
serum) or gonzo antibody at 1:400 dilution of the neat serum.
Foetal human muscle tissue sections were cut in groups of five. One section
was stained with hemotoxylin and eosin. Other slides were subjected to microwave
antigen retrieval and stained with either normal rabbit serum at 1:100 dilution
(negative control), gonzo antibody diluted to 1:100, vivian antibody at a protein
concentration of 1 Opg/ml, or vimentin antibody, which was purchased and used in a
prediluted form.
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Foetal human adrenal gland sections were cut in groups of three. One section
was stained with hemotoxylin and eosin. The remaining two slides were subjected to
microwave antigen retrieval and tested with either normal rabbit serum at 1:100
dilution (negative control), or gonzo antiserum diluted to 1:100.
Adult rat adrenal gland sections were cut in groups of three. One section was
stained with hemotoxylin and eosin. The remaining two slides were subjected to
microwave antigen retrieval and tested with either normal rabbit serum at 1:100
dilution (negative control), or gonzo antiserum diluted to 1:100.
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Chapter 3
Characterisation of Vasopressin Radioimmunoassay
3.1 Principles of radioimmunoassay
The detection and quantification of biologically important molecules has
been a long sought after and subsequently constantly refined technique. In a clinical
environment the rapid and accurate analysis of the content of a particular molecule in
a biological fluid is a vital tool in the diagnosis and monitoring of many conditions,
and radioimmunoassay (RIA) has proved to be an extremely versatile tool for this
purpose. The first description of a radioimmunoassay was by Yalow and Berson in
1960 - a radioimmunoassay for insulin (231).
The ability to quantitatively measure a molecule in a radioimmunoassay is
dependent on the creation of a standard displacement curve (or a standard curve).
The "ligand", commonly the molecule of interest, is incubated with the "binder", and
the "tracer" (232). The tracer is a radioactive isotope, incorporated into the molecule
of interest, and the binder is a specific antibody with a high affinity for the molecule
of interest. A radioimmunoassay works according to the laws of mass action - they
are competition binding assays. Increased binding of unlabelled ligand leads to a
proportional decrease in binding of tracer, as the two molecules bind to the same site
on the antibody. By incubating known increasing concentrations of a standardised
preparation of the ligand with a constant amount of tracer, separation and
quantification of the bound portion of tracer from the free portion makes it possible
to create a standard curve. Thus, the presence and amount of the molecule of interest
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in a sample can be established by replacing standard with sample and incubating
with the same amount of tracer and concentrations of binder. The distribution of the
tracer between the bound and free portions will be equivalent to a concentration of
standard on the standard curve. By simple extrapolation from this curve, the
concentration of the molecule in the sample is found.
3.2 Characterisation of a radioimmunoassay
A radioimmunoassay can be characterised and standardised using four
criteria: accuracy, precision, specificity, and sensitivity.
3.2.1 Sensitivity
Chard describes sensitivity as the "minimal detection limit of an assay", or
"the least concentration of unlabelled ligand which can be distinguished from a
sample containing no unlabelled ligand" (232). This is found by comparing the
standard deviation observed in samples of zero standard with the standard deviation
observed in samples containing decreasing concentrations of ligand. The
concentration of ligand at which the lowest possible binding of standard is higher
than the highest possible binding of standard in a sample with no ligand is taken as
being the sensitivity of the assay.
3.2.2 Accuracy
The accuracy of an assay is the closeness to which the estimated
concentration of a sample approximates the real concentration. The most important
factor in establishing an accurate assay is the existence of a standard preparation of
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the ligand, the concentration and purity of which are known in themselves to a high
degree of accuracy. Typically, this is found by the combination of many studies
carried out in different laboratories to produce a consensus figure for a preparation or
pool of material that is then be used as a standard, a benchmark by which an assay
can be prepared with a high degree of confidence.
Accuracy is affected by the specificity of the binder. Any factor in the sample
that alters the binding characteristics of the assay will alter the accuracy of the assay.
Accuracy is also affected by the precision of an assay, but this is treated as a separate
criterion and is discussed below.
Accuracy can be described in terms of the between assay variation. This is
based on the measurements of aliquots from a large pool of a sample in sequential
assays. The aliquot is treated as a single sample, and as such assayed alongside other
unknown samples - use of a larger number of replicates within an assay would give a
false impression of the variation between assays (232).
Such a measure of between assay variation is a form of quality control.
Quality control allows an individual assay to be accepted or rejected on the basis of
accuracy. This is done by both statistical and instinctive examination of the
information provided by the quality controls to judge that the assay is working
accurately and precisely inside control limits (232). Chard sets out several necessary
characteristics of samples to be used for the monitoring of an assay: the samples used
should contain the molecule of interest in either the buffer which the assay uses or in
the biological fluid the assay is intended to evaluate; there should be enough of the
pool so that it can be made into aliquots to supply controls for many months or even
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years; and the pools should be chosen (or made) such that their concentrations
represent high, medium, and low values in the standard curve.
3.2.3 Precision
The precision of an assay is the variation in estimated concentration with
which a sample is described. It can be thought of as the reproducibility of the
estimate of the molecule of interest in a sample (232). Precision can be described by
the use of repeated determinations on either a quality control pool or one or more
unknown samples within a single assay. Commonly, the mean and the standard
deviation are used to calculate an expressed precision as a percentage of variation of
the estimate from the mean.
3.2.4 Specificity
Establishing that the antibody only has affinity with the molecule of interest
and not with those that have structural similarity is also important. A good example
is the neurohypophyseal hormones themselves. They have very similar primary
structures, differing from each other by only one or two amino acids, and so it is vital
to demonstrate the specificity of an assay in order for it to be used with confidence
when measuring hormone levels in samples where more than one peptide hormone
may be found.
3.3 Vasopressin radioimmunoassay
The first RIA for vasopressin was described in 1970 (233). The problems
associated with the development of a vasopressin RIA for use with blood plasma
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samples can be discussed within the context of the four criteria listed to characterise
assays in Section 3.2.
The generation of specific antibodies to the peptide is a first requirement and
problem. Molecules of low molecular weight, like vasopressin, do not elicit a strong
immune response. Although as few as six amino acids will elicit antibodies, and the
peptide alone will give rise to specific antibodies (antibodies to vasopressin were
first reported in 1966 (234), and early examples of are antibodies produced by
animals immunised are listed in (235)), a more effective way to produce antibodies is
to conjugate the peptide to a larger molecule, such as bovine serum albumin (BSA)
or thyroglobulin, rendering it more antigenic (236). The antibodies used in assays
described in this chapter were raised in this manner.
Another problem in vasopressin radioimmunoassay development for the
assay of biological samples is the optimisation of the assay so that it is sensitive to be
able to detect the peptide at the low concentrations it is normally found at. These
circulating concentrations are much lower than many other larger hormones (typical
resting concentrations are of the order of 2pg/ml (237)). In the event of it being
impossible to produce sufficient sensitivity assay through optimisation, an effective
way to get over this hurdle would be to incorporate a concentration or extraction step
prior to the assay itself.
A third potential problem in assays is the interference encountered in assays
of unextracted biological fluids, typically urine or blood plasma. (234, 235). Chard
refers to this interference as "non-specific non-specificity" or "matrix effects" (232).
This interference compromises both the sensitivity and accuracy of the assay - it
commonly leads to an over estimation of the amount of the molecule being
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investigated in the sample. This is ascribed to non-specific high molecular weight
material in the biological fluid that does not change in response to physiological
stimuli (237). Other examples ofmaterial that can interfere in the assay are heparin,
salts and urea, acids and alkalis, nucleic acids and haemoglobin (232). Again, a
solution to this is the extraction of the peptide prior to assay (237); an example of
this is the premeasurement treatment of urine (238).
The aim of the experiments described below was to standardise and
characterise another precise assay that could be carried out in parallel with, or as a
substitute for, the already described assay using tgl antiserum. By comparing the two
it was hoped that data from the two could be related in terms of accuracy. The use of
more than one antibody preparation was employed to confirm the specific nature of
the reported immunoreactivity in foetal muscle extracts, and so validating that the
two assays were significantly comparable was important (187). The cross-reactivity
of the sheep antiserum was investigated using all naturally occurring peptides that
could conceivably interfere with the accuracy of a specific assay for arginine
vasopressin, in order to rule out the immunoreactivity being due to the presence of a
different peptide.
It should be stated that no efforts were made to redevelop the fundamental
steps of the assay beyond those used as standard in the laboratory in which the
experiments were carried out. The constituents of a standard assay buffer were not
modified. The assay was buffered using Tris-HCl solution, but no differences were
observed for the standard curves gained using this buffer from those obtained when a
standard phosphate buffer was used (data not shown). Assay volume was not
investigated, nor was the method for the separation of bound and free phases. Also,
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the tracer was purchased from the same commercial source and was not the focus of
any experimentation beyond the observation that neither the shape of the standard
curves nor the sensitivity were significantly changed by adding double the amount of
tracer in the same volume (data not shown).
The rationale for not optimising the sensitivity of the assay by various
available methods was that it was thought that the immunoreactivity encountered
during the experiments would be of a sufficiently high level to render the actual
value of the lowest detectable dose irrelevant.
3.4 Results
3.4.1 Characterisation and standardisation of anti-AVP sheep antiserum s278
The titration curve for the sheep antiserum s278 is shown in Figure 3.1.
Using this, the serum was diluted to 1/50000 (giving a Bo of 35% of 5000 counts) for
all future binding experiments and assays.
3.4.1.1 Accuracy
The accuracy of the assay was established using the 1st International
Standard for Bioassay. Ampoules are supplied containing the freeze dried residue of
20pg of AVP. It is recommended for use for calibration of reference preparations,
and as such is considered to be an accurate preparation. The accuracy of the assay
was therefore confirmed by establishing that estimated concentrations of samples
conformed to known concentrations of 1st International Standard in the standard. All
other preparations ofAVP were calibrated using this standard.
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The accuracy of measurement of a sample in an s278 radioimmunoassay was
defined by 20 different measurements of the quality control pools in separate assays.
The high concentration quality control was set at 600pg/ml. The mean estimated
concentration was 622±75pg/ml - a variance of 12%. The mid-point quality control
was set at 150pg/ml. The mean estimated concentration was 162±12pg/ml - a
variance of 7%. The low concentration quality control was set at 40pg/ml. The mean
estimated concentration was 40±6pg/ml - a variance of 16%.
After these limits of accuracy were established, assays where one or more of
the quality controls were outside these limits were rejected and the assays performed
again.
3.4.1.2 Precision
The variation of measurement of a sample within an assay was examined by
the assay ofAVP in 20 replicate tubes of the same sample in one assay.
The 1st International Standard for Bioassay was used to generate three
sample concentrations at different points on the standard curve. These were
800pg/ml, 400pg/ml, and 40pg/ml. The 800pg/ml sample was estimated to contain
802±53pg/ml. This is a variance of 7%. The 400pg/ml sample was estimated to
contain 397±23pg/ml. This is a variance of 6%. The 40pg/ml sample was estimated
to contain 43±5pg/ml. This is a variance of 13%.
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3.4.1.3 Sensitivity
The sensitivity of the assay was examined by the serial dilution of AVP
standard. Nine tubes were assayed for each concentration along with nine tubes
containing only assay buffer. The results are shown in Figure 3.2. Figure 3.2 also
shows the two lowest concentrations set against the data for the Bo tubes. The figure
demonstrates that it would not be possible to distinguish the lowest dose from the Bo,
but binding of tracer in the presence of 7.8pg/ml AVP is sufficiently different from
the observed Bo for estimates of concentration at this level to be quoted confidently.
No further refinement of the sensitivity was carried out, and so it is only possible to
say that the assay has a sensitivity of at least 7.8pg/ml.
3.4.1.4 Specificity
The effect of closely related peptides on the binding of AVP to an aliquot of
the s278 antiserum was examined using standard preparations of peptides. The
resulting displacement of binding due to antibody cross reactivity is shown in Figure
3.3.
Cross reactivity can be defined as the amount of a material required to
displace 50% binding (of Bo) of the tracer to the antibody, compared to the amount
of reference standard required to do the same (239). Using this definition, the cross
reactivity can be expressed as a percentage of the amount of standard. Thus, the s278
antiserum has a cross reactivity of 12% with LVP, 0.1% with AVT, and less than
0.001% with oxytocin.
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3.4.2 Comparison and correlation of tgl assay and s278 assay
The binding curves of radioimmunoassays using the antisera s278 and tgl
when incubated with varying concentrations ofAVP are shown in Figure 3.4.
The results of assays in which the same samples were measured are shown in
Figure 3.5. Analysis of the estimated concentrations of the samples gained from the
two assays by a paired Students t-test showed that there was a non-significant












FIGURE 3.1 Titration of s278 sheep antiserum
s278 pooled sheep serum was diluted serially in assay buffer and incubated
overnight at 4°C with 125I-AVP (5000 counts per tube). Bound tracer was then
precipitated using second antibody/PEG mixture, separated by centrifugation as for the
radioimmunoassay, and counted. Binding was calculated as a percentage of the total
counts. This titration was used to select the dilution at which the serum was used in the
radioimmunoassay.
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FIGURE 3.2 Sensitivity of s278 radioimmunoassay - lowest detectable dose
(legend overleaf)
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FIGURE 3.2 Sensitivity of s278 radioimmunoassay - lowest detectable dose
To determine the lowest concentration of AVP that the s278 assay could detect in the
described form, a serial dilution of AVP standard was incubated with antibody and
tracer as described for a radioimmunoassay (n=9). Bound tracer was separated as for the
radioimmunoassay, and counted. The percentage of tracer bound was calculated using
the total counts added.
A
Shows that the amount of tracer that was bound decreased with increased concentration
of added AVP.
B
The standard deviation of percentage of bound tracer was calculated for all points and
the two lowest concentrations are shown along with that of the Bo. It can be seen that
lowest concentration ofAVP cannot be distinguished from the Bo, but it is possible to do
so with the next highest concentration. Sensitivity can be described, therefore, as the
lowest detectable concentration of the radioimmunoassay using s278 in the described
form, and is at least 7.8pg/ml.
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Peptide concentration added (M)
FIGURE 3.3 Cross reactions of the s278 serum to peptides other than AVP
The ability of the s278 antibody to detect arginine vasopressin specifically was tested
using three peptides structurally very similar to AVP, and which could potentially be
present in samples.
s278 antiserum diluted to 1/50000 was incubated overnight at 4°C with varying
concentrations of each peptide. I25I-AVP (5000 counts per tube) was then added and
incubated overnight at 4°C. Bound tracer was then precipitated using second
antibody/PEG mixture, separated by centrifugation, and counted. Bound tracer was
compared to the amount of tracer bound in the absence of any peptide (Bo)and data are
presented as percentages, signifying displacement of tracer by the non labelled peptides.
Cross reactivity is generally defined as the amount of a molecule required to displace
50% of the tracer (marked in the figure) compared to the molecule of interest, in this
case AVP, and presented as a percentage. Thus, the s278 antiserum has a cross reactivity
of 12% with LVP, 0.1% with AVT, and less than 0.001% with OT.
AVP = arginine-8-vasopressin OT = oxytocin
LVP = lysine-8-vasopressin AVT = arginine vasotocin
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AVP concentration (pg/ml)
FIGURE 3.4 Sensitivity of s278 antiserum - creation of standard curve
In order to determine the range of sensitivity of the s278 antibody, antiserum
diluted to 1/50000 with assay buffer was incubated overnight at 4°C with varying
concentrations of standard AVP. 125I-AVP (5000 counts per tube) was then added and
incubated overnight. Bound tracer was then precipitated using second antibody/PEG
mixture, separated by centrifugation, and counted. Bound tracer in the sample tubes was
compared to the amount of tracer bound in the absence of AVP (B0j designated 100%)
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FIGURE 3.5 Comparison and correlation of tgl and s278 assays
Known concentrations of standard AVP were measured as unknowns in standard
radioimmunoassays using both the tgl and s278 antibodies. A: 200, 100, 50, and
25pg/ml were measured. B: 100, 50, 25, and 12.5pg/ml were measured.
A paired Student t-test analysis showed a non-significant difference (p>0.05) between
the estimated doses from the two assays.
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3.5 Discussion
The results in this chapter show that the sheep antiserum s278 can be used in
a radioimmunoassay for AVP. s278 had been used to demonstrate immunoreactivity
in foetal muscle previously (187), and in the interests of conformity would be used
again for the same purpose. It was therefore necessary to standardise the assay.
The evaluation of the cross reactivity of the s278 antiserum under assay
conditions with peptide analogues of AVP that differ by only one or two amino acid
residues, indicates that an assay involving this antiserum is suitable for assay of
vasopressin under conditions where there might be other peptides in the samples,
such as assays of pituitary extracts where oxytocin is present. This specificity avoids
a need for further separation steps, for example the use of HPLC. Under the
controlled conditions of the RIA, evaluating standard AVP diluted with assay buffer,
the assay will provide the same value of estimated AVP as that supplied by the more
sensitive assay using tgl as binder.
The within assay and between assay variations for the assay using s278
antiserum compare favourably with the reliability of other reported
radioimmunoassays for AVP (228, 238 , 240-245).
With reference to circulating physiological levels of AVP, an assay using the
s278 antiserum in the form presented cannot be used for the measurement of AVP
from plasma, serum, or urine without a prior step to concentrate the peptide, because
the low concentration it is found at in those fluids is lower than the sensitivity of the
assay. Though it is conceivable that optimising the detection limits of the assay
would permit the use of the RIA for this purpose, the s278 assay as described should
be well suited for the role of the assay of the much higher expected concentrations of
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AVP from tissue extracts. In this respect, the use of s278 antiserum assay in the
estimation of high concentrations of vasopressin extracted from tissues may be
preferable to using tgl for this purpose. Use of the s278 assay to examine higher
concentrations of AVP was considered viable and was considered a less costly




Radioimmunoassay of Samples Containing Acetic Acid
4.1 Introduction
In Chapter 3 the characterisation of a radioimmunoassay to quantify high
concentrations of AVP was described in anticipation that, according to published
observations, skeletal muscle would be a source ofAVP.
The starting point for the work described within this chapter is a report of
high levels of specific vasopressin immunoreactivity from a novel source - foetal
human skeletal muscle (187). In that report, radioimmunoassay is used in
conjunction with additional techniques to demonstrate significant levels of
apparently specific vasopressin immunoreactivity. Muscle tissue was homogenised
in molar acetic acid; at low pH, neurohypophyseal peptides are stable and tissue
enzymes are inactive, and so many of the solutions used in the homogenisation of
tissues to extract peptides are deliberately acidic. The homgenate was placed in a hot
water bath for at least ten minutes and centrifugued at 25,000g for an hour. The
supernatant was either "assayed directly" or further purified before being assayed.
The assay of tissue extracts for AVP appears to pose slightly different
problems than those encountered when attempting to estimate the concentration of
AVP in biological fluids. The sensitivity of an assay should not be an issue. For
example, concentrations of peptide present in posterior pituitary glands will be very
high, and the ability to dilute the sample will remove the problem of detection limits
as well as non-specific interference as a factor affecting the accuracy of an assay of
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extract from these tissues. However, there is still a need for antibodies specifically
recognising AVP. The given example of posterior pituitary glands is still relevant.
Oxytocin is present in the same tissue, and so an antibody recognising this peptide as
well as AVP would give a inaccurate estimate of the concentration of AVP in a
sample.
A large part of the need for a radioimmunoassay in experiments establishing
novel immunoreactivity is to establish parallelism in the dilution of any sample to
that seen in the standard preparation. For example, when a sample is diluted by half,
the assayed immunoreactivity will halve correspondingly. Non-specific interference
in a high estimate of concentration does not dilute in same manner.
The aim of the experiments described in this chapter was to validate the
published observations of immunoreactivity in the extracts of foetal muscle in 1M
acetic acid contained in several reports (187, 217, 218).
4.2 Results
The direct assay of any sample containing 1M acetic acid resulted unfailingly
in a complete lack of binding of any tracer, giving rise to a very high and imprecise
estimate of AVP concentration (data not shown). Accordingly, assays were carried
out on samples that had been diluted five or ten fold (yielding concentrations of
0.2M and 0.1M acetic acid in the sample). Data resulting from these assays are
shown in Figure 4.1. A pattern of dilution is seen, where there is an initial high
estimate for the concentration of AVP at 0.2M acetic acid, dropping to a lower
estimate of peptide concentration at 0.1M and dropping to a very low level at 0.05M-
commonly below the lowest detectable limits of both assays. Samples were assayed
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in both the s278 and tgl assay at these concentrations of acid with the aim of
confirming that measurements from the two assays were comparable, but it was
obvious from these assays that the measurements were markedly different, resulting
in markedly different estimates of AVP content in foetal muscle samples. Potential
causes of this imprecision were examined.
The assay of diluted acetic acid containing different concentrations of BSA is
shown in Figure 4.2, hinting that the presence of acid in the sample is responsible for
a significant portion of this apparent immunoreactivity at relatively higher
concentrations of acid.
Further samples of muscle were homogenised and diluted and assayed only
using the tgl assay. The same samples were also supplemented with standard AVP,
diluted and assayed, and the resulting changes in the estimates of AVP are shown in
Figures 4.3 and 4.4. The pattern of dilution was seen to change when standard AVP
was introduced. At all higher concentrations of acetic acid the estimated AVP
concentration never approximated those expected; only at the two lowest
concentrations of acid did estimated levels of AVP conform to those that would be
predicted.
Acidified extracts of foetal muscle were neutralised using 2M Tris and
assayed. The resulting immunoreactivity is shown in Figure 4.5. Taking into account
the blank samples, and the lack of parallelism in the dilution pattern of the
neutralised samples, it was concluded that the observed immunoreactivity was due to
an undefined background effect of the acetic acid.
An apparent relationship between the ratio of the weight of tissue to the
volume of acid the tissue a sample is extracted in, and the observed
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immunoreactivity in that sample, is shown in Figures 4.6 and 4.7. The
immunoreactivity decreased when the ratio of the weight of tissue extracted, to
volume of acid the tissue is extracted in, increased. This was shown to be
irrespective of gestation age, as the same muscle samples were extracted with
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FIGURE 4.1 Effect of muscle tissue on vasopressin estimations in acetic acid
extracts
Different weights of muscle tissue were each homogenised in the same volume of 1M
acetic acid (8ml total volume). After centrifugation, supernatants were diluted with assay
buffer so that the concentration of acetic acid was the same as that used in other
experiments. The solutions were then assayed using both the s278 and tgl antibodies.
0.05M acid samples were also assayed, but values were below the lowest detectable
doses of both assays and so are not presented.
A - Sample was acetic acid without muscle tissue.
B - Sample was supernatant of 8ml of 1M acetic acid used to homogenise 1.2g of
muscle from a 15 week old foetus
C - Sample was supernatant of 8ml of 1M acetic acid used to homogenise 2g of muscle
from a 16 week old foetus
D - Sample was supernatant of 8ml of 1M acetic acid used to homogenise 2.5g of
muscle from a 19 week old foetus
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FIGURE 4.2 Demonstration of vasopressin immunoreactivity in apparent blanks
0.2M acetic acid was prepared by dilution of 1M acetic acid using assay buffer. BSA
was then dissolved in this solution to give concentrations of 100 and 50mg/ml. Further
dilutions were made with assay buffer, and all the resulting solutions were assayed as
samples in standard radioimmunoassays.
A: Demonstrates the immunoreactivity observed when the samples were assayed using
the using the s278 antibody.
B Demonstrates the immunoreactivity observed when the samples were assayed using
the using the tgl antibody.
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A - Adult rabbit muscle
Acetic acid concentration in sample (M)
B- Foetal human muscle
Acetic acid concentration in sample (M)




FIGURE 4.3 Effect of dilution on apparent vasopressin immunoreactivity in tgl
radioimmunoassay
It had been previously demonstrated that the two antisera to vasopressin had markedly
different sensitivities to the presence of acetic acid in the assay. The effect of dilution
with more acetic acid, and the effect of the amount of tissue in the sample was
investigated. Reported values for AVP were gained using the tgl assay, and so no assays
were done using s278.
Three different weights of adult rabbit muscle were homogenised in the same volume of
1M acetic acid. The same weights ofmuscle from a human foetus were homogenised,
again in the same volume of acid. The homogenates were centrifuged, and aliquots of
the supernatant were diluted with assay buffer and assayed using tgl antiserum.
Sample A - Acetic acid containing no tissue extract
Sample B - Aliquot of acetic acid used to extract 0.5g of adult rabbit muscle
Sample C - Aliquot of acetic acid used to extract lg of adult rabbit muscle
Sample D - Aliquot of acetic acid used to extract 1,5g of adult rabbit muscle
Sample E - Aliquot of acetic acid used to extract 0.5g of foetal human muscle
Sample F - Aliquot of acetic acid used to extract lg of foetal human muscle
Sample G - Aliquot of acetic acid used to extract 1.5g foetal human muscle
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FIGURE 4.4 Effect of acetic acid on detected vasopressin immunoreactivity in
samples supplemented with AVP using the tgl radioimmunoassay
(legend overleaf)
Sample A + AVP
D Sample B + AVP
A Sample C + AVP
-A Sample A + AVP
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FIGURE 4.4 Effect of acetic acid on detected vasopressin immunoreactivity in
samples supplemented with AVP using the tgl radioimmunoassay
It had been previously demonstrated that the two antisera to vasopressin had markedly
different sensitivities to the presence of acetic acid in the assay. The effect of dilution
with more acetic acid, and the effect of the amount of tissue in the sample was
investigated. Published values for AVP in foetal muscle were gained using the tgl assay
of acetic acid, and so no assays were done using s278 to investigate this effect.
Three different weights of adult rabbit muscle were homogenised in the same volume of
1M acetic acid. The same weights ofmuscle from a human foetus were homogenised,
again in the same volume of acid. The homogenates were centrifuged, and 1ml aliquots
of the supernatant were supplemented with 750pg of standard AVP. The samples were
diluted with assay buffer and assayed using tgl antiserum.
Sample A - Acetic acid with no tissue extraction
Sample B - Aliquot of acetic acid used to extract 0.5g of adult rabbit muscle
Sample C - Aliquot of acetic acid used to extract 1 g of adult rabbit muscle
Sample D - Aliquot of acetic acid used to extract 1,5g of adult rabbit muscle
Sample E - Aliquot of acetic acid used to extract 0.5g of foetal human muscle
Sample F - Aliquot of acetic acid used to extract 1 g of foetal human muscle
Sample G - Aliquot of acetic acid used to extract 1,5g foetal human muscle
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FIGURE 4.5 Effect of neutralisation of acetic acid on immunoreactivity of foetal
skeletal muscle extracts
Samples of foetal muscle representative of different ages of midtrimester gestation
were weighed and all homogenised in the same volume of 1M acetic acid (10 ml).
After centrifugation, supernatants were neutralised (to pH 7.2) with 2M Tris.
Undiluted and diluted samples (diluted with assay buffer) were assayed using both
tgl and s278 antisera.
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FIGURE 4.6 Effect of increasing the amount of tissue extracted in the same
volume of acetic acid
Different weights of skeletal muscle from four differently aged foetuses were
homogenised in the same volume of 1M acetic acid. After centrifugation, aliquots of the
supernatant were diluted with assay buffer to give concentrations of the acid of 0.1M
and 0.05M. These samples were assayed using the tgl antibody.
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FIGURE 4.7 Effect on immunoreactivity in a sample of varying the amount of the
same tissue homogenised in the same volume of acetic acid
Different weights of skeletal muscle from four differently aged foetuses were
homogenised in the same volume of 1M acetic acid. After centrifugation, aliquots of the
supernatant were diluted with assay buffer to give concentrations of the acid of 0.1M
and 0.05M. These samples were assayed using the tgl antibody.
For the purposes of demonstrating a correlation, the two sets of data shown separately in
Figure 4.6 were combined on a single graph. All points were treated as a single group.




The data from assays of AVP in tissue extracts containing 1M acetic acid
demonstrate that justifying the quantification of AVP using this method is
problematic. The data presented contradict the theory that it is possible to accurately
measure AVP in samples containing 0.2M or 0.1M acetic acid.
Interpreted literally, Figures 4.1, 4.2, and 4.3 show that not only foetal muscle
but adult rabbit muscle and even acetic acid (apparently containing nothing more
than double distilled water and a small volume of glacial acetic acid, with an assayed
purity of 99.7%) contain high amounts of AVP. Further, the more muscle
homogenised per unit volume of acid, the less AVP the resulting homogenate
contains.
These conclusions are clearly illogical. The traditional method for detecting
non-specific interference of any type is the lack of parallel dilution when comparing
standard and the sample (232). Data gained from the assays of acetic acid containing
only BSA display just that. The obvious conclusion to be drawn is that the
immunoreactivity is nothing more than acid or acetate interference, which decreases
with the dilution of acid in the extraction medium. The effect of the acid is
ameliorated by an increase in concentration of a factor provided not only by foetal
muscle but adult rabbit muscle, suggesting that this factor is not species or
developmentally specific and may simply be something as mundane as a buffering
effect of soluble protein from the tissue in the acetic acid extract, explaining why
increasing the amount of any tissue extracted in the same volume of molar acetic
acid decreases the apparent AVP concentration.
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Further, the selection of the concentration of AVP used in experiments
described in Figure 4.4 was made with reference to the data of Smith and co¬
workers, so that it would be of a comparable scale to that apparently seen in their
samples (187). All the data from assay ofmuscle extracts where no exogenous AVP
has been added suggest that supplementation of samples with standard AVP does not
significantly increase AVP levels already present in any extract.
The acid interference in a vasopressin radioimmunoassay has been noted by
Chard, where an inappropriately high concentration of vasopressin was observed in
an assay of plasma extracted using glass beads. The acid used in the extraction had
not been adequately removed prior to addition of the samples to the assay (235).
Neutralisation of acetic acid completely removed the immunoreactivity observed in
acidic samples (Figure 4.5). The low concentrations in muscle samples were no
higher than that seen in blank samples. Moreover, the estimations provided by tgl
and s278 assays were significantly different - a paired Students t-test generated a p
value of less than 0.001. In assays of standard AVP described in Chapter 2, this was
not observed. Given this, it is concluded that any concentration ofAVP yielded from
the homogenisation of foetal human muscle in those experiments was too low to be
detectable using either assay. Certainly, extraction of twice the weight of muscle in
the same volume did not give rise to twice the amount of AVP in the sample
observed.
The relationship between gestation age and immunoreactive AVP described
by Smith and colleagues was constructed from data provided by the "direct assay" of
acetic acid extracts of foetal muscle (187). Most of the data from which the graph
which displays this relationship was constructed are not available, but those that are
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were examined, and are reproduced in Appendix A (pages 1 -3 of Appendix A are
reproduced, with permission, from the notebook of R. Stephen, Chief Technician,
Department of Child Life and Health, University of Edinburgh Medical School,
Edinburgh, UK). Also reproduced is a summary page where some of the results are
collated (Appendix A, page 4, reproduced, with permission from the notes of R.
Stephen).
The data shown are figures for immunoreactivity apparently based on the
assay of samples that have been diluted 1/5, 1/10, and 1/20 dilutions of acid i.e.
0.2M, 0.1M and 0.05M (the dilutions are marked at the tops of the columns on the
left of each page, together with the note that the assay uses tgl). It is apparent that all
75 samples contain significant amounts of AVP immunoreactivity, and the pattern of
dilution is similar to data obtained from tgl assays performed for this thesis. No data
is shown for the assay of samples diluted to concentrations of acetic acid extract
lower than 0.05M.
The summary page lists some of the samples that apparently are foetal in
origin. They are identifiable as being samples from assays in the notebook by their
autopsy number and the tube number, and are indicated. These samples all have three
lower numbers underneath each of the dilutions, and three large numbers to the right
hand side, which are corrected values for the concentration in the sample; the lower
numbers are multiplied by 5, 10 or 20 where appropriate. In some cases, these
corrected values seem to demonstrate a halving dilution relationship between the
samples. However, the values have already been corrected - they should be
approximately the same after the first correction. It is not known how the figures in
the third column of the summary page (titled pg/ml) were arrived at. The value for
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this immunoreactivity is used to calculate a figure for the AVP content per gram of
muscle by taking in to account the volume the muscle was extracted in, and the
weight of muscle extracted. These figures, unless corrected in some way that is not
noted in the sheets, originate from data that has been demonstrated by experiments
described in this chapter to be, at best, inaccurate, and are used as published evidence
of AVP-ir in foetal skeletal muscle.
Without knowledge of the interference effect of the acetic acid in the tgl
assay, a series of extractions where an increase of gestation age is mirrored by an
increase in the weight of muscle sample used (perhaps caused by the availability of a
larger source of material given the growth of a foetus with time), but not by an
increase in the volume of acid in which the muscle is extracted, would give rise to
data suggestive of a relationship between gestation age and immunoreactivity
specific to AVP when the extracts are assayed and corrected for these factors. Figure
4.6 shows that less tissue extracted per unit volume causes higher apparent
immunoreactivity. Correction for the amount of tissue used in each extraction would
cause a further widening of the difference in content per unit weight between
different weights of extracted sample.
Figure 4.4 shows that direct information about the concentration of
vasopressin in a sample can only be obtained by assaying for AVP in highly diluted
molar acetic acid extracts. A titration of the effect of acid on the assay was not
carried out, but at the very least it can be said that any attempt to use the data from
RIA of acetic acid extracted tissues to provide a single figure of vasopressin content
is complicated by the use of estimations provided by any assay of a sample
containing acetic acid concentrations of 0.05M or above.
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An obvious explanation for the failure to measure AVP in extracts from
foetal muscle is that homogenisation did not liberate vasopressin present in the tissue
due to retention of AVP by a specific or non-specific binding factor. A way of
demonstrating that the homogenisation was effective would be to homogenise
muscle with exogenous AVP included before homogenisation and demonstrate
retention ofAVP, and experiments where this was done are presented in this thesis.
However, boiling and homogenisation were carried out with the aim of
completely dissolving the tissue and removing the activity of any factor acting to
reduce AVP levels in the muscle tissue. The method of extraction used for these
experiments is essentially the same as that described by Smith and co-workers. One
difference in the present study was the use of a lower centrifugation force in the
centrifugation of tissue homogenates (12,000g compared to the 20,000g used by
Smith et at). But this difference strengthens the conclusion that a significant
proportion of the immunoreactivity seen in the RIA is non-specific. Higher g-forces
would reduce the general protein concentration in the extract supernatant, resulting in
higher levels of apparent immunoreactivity. The pattern that is observed in
homogenisations of different weights of the same muscle sample (Figures 4.6 and
4.7) would be unchanged.
In conclusion, it was not possible to demonstrate genuine AVP
immunoreactivity in the assay of tissue extracts in which concentrations of acetic
acid were present that interfered with the accuracy of the assay. Extracts containing
1M acetic acid had to be diluted more than forty times to demonstrate supplemented
immunoreactivity that diluted parallel with a standard curve from an AVP
radioimmunoassay.
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However, the tgl assay was set up according to instructions so that it would
have a lowest detectable limit of 1.56pg/ml of AVP. Concentrations of less than
60pg/ml in the original extract could not then be reliably demonstrated using the tgl
assay. In this respect, the use of an extraction step was indicated to determine
whether there were concentrations of vasopressin in foetal muscle that were much
lower than those reported by Smith and co-workers, but which may nonetheless be of
physiological significance in the maturation of foetal skeletal muscle.
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Chapter 5
Solid Phase Extraction of Vasopressin From Homogenised
Tissues
5.1 Introduction
The extraction of vasopressin from tissue uses the same principles and
techniques as the extraction of vasopressin from biological fluids. Direct, accurate
measurement of peptides in blood plasma and serum is compromised by the presence
of non-specific interference altering the estimated concentration, as well as the
enzymes present in many fluids and tissues from normal and pregnant individuals
that have shown to be capable of degrading peptides (246). Thus, an extraction step
prior to an assay is advocated by many investigators in many cases (241, 247-249).
The advantages of extraction of AVP for assay from biological fluid samples
apply equally to tissues. Extraction from a tissue is also obviously vital in order to
liberate the peptide from the tissues, preferably into a stable environment. The
removal of accompanying interfering matter or degrading enzymes allows more
accurate estimations. Concentration of the sample provides an increased sensitivity
and will allow dilution of the sample to establish parallelism, thus conveying a
quality of specificity to the immunoreactivity.
The practical criteria for an extraction procedure in a clinical situation are set
out by Chard (232). Although the need for rapid throughput of samples is less during
a laboratory investigation, these criteria can be applied to all extraction procedures.
The extraction must be quick and simple, to allow a large number of samples to be
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processed in the time available. The extraction should be specific, that is the sample
should be concentrated into a volume considerably smaller than that of the original,
but at the same time it should not concentrate the interfering factors it is sought to
remove. The recovery of the extraction should be better than 50%, with good
reproducibility. Chard is quite adamant on this, and he reiterates that it is much more
desirable to have an extraction that reliably and repeatedly extracts with an efficiency
of 60% than one that only variably extracts with an efficiency of 90%. The extraction
should not affect the binding properties of the target of the extraction, and the
reagents and materials used should be readily available and have little variety
between batches.
Various methods have been used for the extraction of peptides. Typically,
either acetic acid or hydrochloric acid is used as an extraction solvent, as
neurohypophyseal peptides are stable at lower pHs (3). Tables 5.1 and 5.2 show
examples of different methods of extraction. Recently, the methods of choice for the
extraction of peptides have been limited to either Sephadex G-25 or G-50 gel
filtration or solid phase extraction. Gel filtration elutes molecules of higher
molecular weight before the lower weight peptides of interest are eluted. Also,
because there is no loss of sample between homogenisation and assay, it can be
assumed that the profile obtained is a good reflection of the constituents of the tissue
extract.
Solid phase extraction uses the specific physical (but not chemical) binding
of molecules to an adsorbent, allowing other non-specific substances to be washed
away. The bound peptide is then eluted, thereby making it available for assay. As can
be seen from Table 5.2, octadecasilyl silica (C18-silica) is the most commonly used
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adsorbent for the extraction of peptides. C18-silica has been used in HPLC
separations of peptides (250, 251), and in the solid phase extraction of peptides from
biological fluids (252, 253). Based on the work of Bennett, the same procedure was
used to extract pg amounts of vasopressin from biological fluids (LaRochelle and
North were the first to describe use of this method with neurohypophysial peptides
(249), also (241, 254, 255)). Recoveries obtained using this method are typically
quoted as being 70-85%.
The use of C8-silica in the extraction of vasopressin from plasma has also
been described (228). Van de Heijning and co-workers found that C8-silica
extraction was a more convenient and consistent method of extraction than other
solid phase extraction media. Recoveries of 85-96% were achieved, with an apparent
lower retention of interfering factors on the columns. Based on the data of Van de
Heijning and co-workers, it was decided to use 500mg C8-silica cartridges for the
solid phase extraction of vasopressin from tissues.
Experiments described in the first part of this chapter were carried out in
order to evaluate and validate the use of C8-silica cartridges as part of a procedure to
extract vasopressin at high or low doses, and as a method of removing the acetic acid
interference encountered in the direct assay of tissues homogenised in 1M acetic
acid, described in Chapter 4.
Foetal human skeletal muscle was extracted using the established method to
attempt to demonstrate the presence of vasopressin as reported by Smith and co¬
workers (187). Foetal human pituitary and adrenal glands and rat adult adrenal
glands were extracted in the same manner as positive controls. Adult rabbit skeletal







Urine Vycor glass 75% (269)




TABLE 5.1 Methods of extraction of vasopressin from biological fluids
When urine or plasma are assayed directly, a high background is frequently observed

















C18 SPE 85% 50mM HC1 Gel filtration and
RIA
(120)
Blood vessels C18 SPE 85% 1MHC1 RIA (114)
Testis C18SPE 85% 0.1M Acetic acid Gel filtration and
RIA
(139)
Pancreas C18SPE 85% 1,0M Acetic acid RIA (153)










None n/a 1,0M Acetic acid Centrifugation and
direct RIA, HPLC
(187)
TABLE 5.2 Methods of vasopressin extraction from tissues
Different tissues have been reported to contain high levels of vasopressin
immunoreactivity after homogenisation and extraction. Further work to establish
physical characteristics of the immunoreactivity was done in some cases,
n/a = not applicable to this method
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5.2 Results
The data for the standardisation of the C8-silica cartridge extraction step are
summarised in Figure 5.1. When vasopressin was extracted from acetic acid, a
consistent recovery over 80% of amounts of vasopressin ranging from lOpg to lOng
was achieved.
When a concentration of vasopressin selected to be equivalent to reported
doses in foetal muscle was passed through a C8-silica cartridge after addition to the
supernatant of homogenised muscle (both foetal human muscle and adult rabbit
muscle), this high recovery dropped, and such a drop in recovery could be related to
the ratio of the amount of muscle extracted to the volume of acid used in the
homogenisation (Figure 5.2). A reduced recovery was also seen when a similar
amount of standard vasopressin was added to the acetic acid prior to its use in the
homogenisation of a muscle sample, and so all muscle samples were extracted using
lg of tissue and lOg of acetic acid to prevent variation in the extraction efficiency of
different samples.
When lower amounts of vasopressin, lOOpg and 50pg, were added, estimates
of the immunoreactivity were actually higher than those obtained from the C8-silica
cartridge extraction of equivalent amount of vasopressin in 1M acetic acid. Similarly,
low levels of vasopressin immunoreactivity were detected in the radioimmunoassay
of C8-silica cartridge extracts of foetal muscle, and the data from these assays are
summarised in Figure 5.3. The concentrations of the immunoreactivity was rarely
ever high enough to allow parallel serial dilution of the sample, and the
concentrations shown are estimations of the undiluted sample in the assay buffer
used to dissolve the dried pellet of the C8-silica extraction.
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Parallelism was established in the assay of C8-silica cartridge extracted foetal
human adrenal and posterior pituitary glands. The content of vasopressin in foetal
human adrenal and posterior pituitary glands are summarised in Figures 5.4 and 5.5.
Sephadex G-25 chromatography was used to characterise the mobility of
immunoreactivity found in extracts of tissue. Using synthetic AVP, tritiated synthetic
AVP, and AVP from a foetal posterior pituitary gland extract, it was possible to
obtain a consistent peak of vasopressin immunoreactivity at one volume elution past
the void volume (Figures 5.6).
No immunoreactivity or radioactivity were observed in the elution of
synthetic vasopressin and 3H-AVP just after the elution of the void volume, but
displacement of tracer binding was apparent just after the void volume in the elution
of pituitary gland extract, and when tritiated vasopressin was added to foetal human
muscle extract, a small peak of activity was seen at the same volume of elution
(Figure 5.6B), showing that it is possible for AVP to interact with higher weight
molecules that cause it to be eluted much earlier than 'free' vasopressin.
Peaks of immunoreactivity were found at the void volume when extracts
from foetal human adrenal glands were loaded onto the Sephadex G-25 column. The
subsequent analysis of a pooled sample of foetal adrenal glands is in shown in Figure
5.7.
This early peak of immunoreactivity was also observed in the elution of acid
extracts from individual muscle samples. Of six individual muscle samples
examined, two did not show any immunoreactivity. Four others displayed
immunoreactivity after the elution of one void volume. However, no later peak of
immunoreactivity could be detected (data not shown). It was attempted to generate a
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peak of immunoreactivity at the same volume as that found with synthetic, tritiated
or foetal pituitary AVP using larger amounts of pooled extracts of muscle and the
results of this are shown in Figure 5.8. A very small level of vasopressin is
































Amount of vasopressin added prior to C8 silica solid phase extraction
FIGURE 5.1 Physical recovery of AVP after solid phase extraction using C8-silica
cartridges
Known amounts of AVP were added to 9ml aliquots of molar acetic acid and extracted
using C8 silica cartridges. Eluates were either assayed using the s278 or tgl antibody, or
counted when 3H-AVP was used. Recovery efficiencies are presented as percentages of
total amount ofAVP added as determined by RIA or data from counted beta radiation.
* indicates use of 3H-AVP in these experiments
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FIGURE 5.2 Effect of weight of tissue in extract on efficiency of recovery of AVP
by C8-silica cartridges
The effect of the presence of muscle tissue on recovery of AVP from acetic acid was
investigated.
A Different weights of muscle were homogenised in the same volume of 1M acetic
acid (9ml). After centrifugation, the supernatant was supplemented with 750pg of
standard AVP (as determined by the direct radioimmunoassay of the AVP solution),
thoroughly mixed, and the AVP extracted using C8-silica cartridges.
B Aliquots of known concentrations of AVP (determined by direct
radioimmunoassay of the standard solution) were added to a set volume of acetic acid
(10ml). This was then used to homogenise samples of foetal muscle and rabbit muscle
that had been divided into equal weighed portions.




































FIGURE 5.3 Relationship between gestation age and vasopressin level in foetal
muscle samples
To determine the levels of vasopressin in foetal muscle, lg portions of muscle from
foetuses of varying gestation ages were homogenised in the same volume of 1M acetic
acid (10ml). After centrifugation, supernatants were extracted using C8-silica cartridges.
The resulting samples were raised up in assay buffer and assayed using s278 antiserum.
Measurements of AVP in the samples are shown plotted against weight (A) or foot




FIGURE 5.4 Vasopressin content of acetic acid extracted human foetal adrenal
glands
Adrenal glands from foetuses of varying gestation ages were homogenised in
10ml of 1M acetic acid. After centrifugation, the supernatants were extracted using C8-
silica cartridges. The resulting eluates were dried down, raised up in assay buffer and
assayed using the s278 antibody. The resulting values for the total adrenal content are
plotted against foetus weight (A) and foot length (B) to demonstrate the change in






FIGURE 5.5 Vasopressin content of acetic acid extracted human foetal posterior
pituitary glands
The entire dissected middle cranial fossa including the posterior pituitary glands from
foetuses of varying gestation ages were homogenised in 1M acetic acid. After
centrifugation, the supernatants were extracted using C8-silica cartridges. The resulting
eluates were dried down, raised up in assay buffer and assayed using the s278 antibody.
The resulting values for the total gland content are plotted against foetus weight (A) and
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FIGURE 5.6 Standardisation of the gel filtration of AVP
(legend overleaf)
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FIGURE 5.6 Standardisation of the gel filtration of AVP
A: In order to standardise the elution volume of AVP, standard vasopressin was eluted
using Sephadex G-25. Quantities of synthetic AVP (2ng) in 2 ml aliquots of 1M acetic
acid were added to the Sephadex columns. The eluates were collected in fractions of 1 ml
and assayed using the s278 antiserum.
A: A whole pituitary gland from a foetus (Estimated age 19 weeks) was homogenised in
8ml of 1M acetic acid. After centrifugation a 2ml aliquot of the supernatant was applied
to the column. Eluted fractions of 1ml were assayed using the s278 antiserum.
B: 3H-AVP with an activity equivalent to 2ng was added to 12ml of acetic acid and
mixed. A 2ml aliquot was loaded onto the Sephadex G-25 columns. Fractions of 1 ml
were collected and aliquots were counted after addition of liquid scintillant.
B: The same volume of acetic acid, containing the same amount of tritiated AVP, was
used to homogenise lg ofmuscle from a 17 week old foetus. After centrifugation, 2ml of
the supernatant was added to the Sephadex column. Fractions of 1ml were collected and



















Figure 5.7 Elution of immunoreactivity from extracted foetal adrenal gland
(legend overleaf)
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Figure 5.7 Elution of immunoreactivity from extracted foetal adrenal gland
A: Foetal human adrenal glands (no gestation ages were noted) with a combined weight
of 3g were homogenised in 10 ml of 1M acetic acid. After centrifugation, 2ml of the
aliquot was loaded onto the Sephadex G-25 column and eluted. Fractions of 1ml were
collected. Every other eluted fraction of 1ml was assayed using the s278 antiserum.
B: The alternate tubes from the immunoreactivity around the void volume were pooled
and C8-silica extracted. The same was done with fractions leading up to the AVP
associated peak (odd numbered fraction volume from 39 to 45), and fractions on the
down slope of this peak (fractions 47 to 53). The resulting concentrated samples were
raised up in assay buffer, filtered using lOkDa cutoff filters, and the filtrates assayed
using the s278 antibody assay. The measurement from the concentrated sample from the
void volume fractions was below the lowest detectable limit, but the samples from the






























Figure 5.8 Identification of AVP-like immunoreactivity in foetal human skeletal
muscle
Foetal muscle samples that, according to assays summarised in Figure 5.3, contained
higher amounts of AVP were identified and duplicate homogenisations and C8-silica
extractions carried out. The resulting samples were dissolved into small volumes of hot
1M acetic acid, combined, and loaded onto a Sephadex G-25 column as a 2ml sample. A
low but significant level of immunoreactivity was observed in ALL fractions, until two
column volumes had passed through the column (data not shown). This
immunoreactivity did not exceed 17pg/ml in any of the fractions. Accordingly, the
remainder of the samples were re-extracted in groups of ten fractions through separate
C8-silica cartridges. An aliquot of 150pl was removed for assay, and the remaining
solutions were filtered using a lOkDa molecular weight cut off filter, and the filtrate
assayed for vasopressin. A very small level of AVP was seen at both the void volume
and the approximate volume at which AVP would be expected to be eluted to appear in
from the standardisation experiments.




5.3.1 Posterior pituitary glands
The experiments described in this chapter were carried out to assess the
potential of using a C8-silica solid phase extraction step in the quantification of
vasopressin in tissues by radioimmunoassay, and so to demonstrate the presence or
otherwise of immunoreactivity due to authentic vasopressin in foetal human skeletal
muscle. The earlier aim was achieved by showing that synthetic vasopressin could be
reproducibly separated from 1M acetic acid contamination at concentrations
encountered in physiologically relevant concentrations. The C8-silica cartridges
showed no evidence of saturation even when used to isolate as much as lOng of
synthetic vasopressin. When foetal pituitary glands were subjected to
homogenisation followed by C8-silica cartridge extraction, measured levels of
vasopressin were consistent with those reported elsewhere. Data summarised in
Figure 5.5 reflect an increase in the vasopressin content of pituitary glands correlated
with increases of foot length and foetal weight. Schubert reports a range of 2ng in
foetuses aged 15 weeks to 78ng in foetuses aged 19 weeks (22). Burford and co¬
workers report of lng at 11 weeks gestation to lOOOng at 28 weeks gestation (201).
Figure 5.5 represents extractions of pituitary glands from foetuses of 14 to 19 weeks
gestation age. The range of estimated vasopressin in experiments performed above
was 5ng to 5lng per gland. The samples for this study were dissected and frozen
between 1 and 2 hours after expulsion. Schubert and co-workers obtained foetal
pituitary samples, which were frozen on dry ice immediately after foetal expulsion
for their study, and as such undoubtedly reflect more accurately the content of
developing foetal posterior pituitary glands. Nonetheless, the similarity of the data
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establishes the validity of the use of C8-silica cartridge extraction for the isolation of
vasopressin from highly concentrated samples in 1M acetic acid.
5.3.2 Skeletal muscle
The C8-silica extraction of exogenous vasopressin from samples containing
components of muscle showed a lower recovery of peptide, and this reduction in
recovery was related to the amount of muscle to volume ratio used for
homogenisation. One explanation for this finding is that the high concentration of
protein in the extract interferes with the interaction of the peptide and the resin,
causing a lower retained fraction of peptide. However, the recovery was still of a
sufficiently high level to justify proceeding without modification of the extraction
beyond controlling the volume of acid used in homogenisation and the weights of
foetal muscle extraction, so that recovery would be consistent for all extractions.
Immunoreactivity was present in many foetal muscle samples, to the extent
that it affected the recovery efficiency of low doses of exogenous AVP, but this
immunoreactivity was demonstrated to be interference in the radioimmunoassay due
to the presence of a substance of higher molecular weight than vasopressin. Even
when samples were concentrated to a high degree (more than twenty times), little
immunoreactivity that either eluted at the volume of free synthetic or pituitary
vasopressin or diluted in parallel with synthetic vasopressin was observed. The
possibility that more of the vasopressin is retained in the high molecular weight
fraction of the filtration cannot be wholly discounted. Exogenous 3H-AVP was found
in this fraction when introduced to the post-homogenisation supernatant. However, in
all cases where this retention of vasopressin was observed, it was accompanied with
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a much larger amount of vasopressin immunoreactivity (or radioactivity) at the
volume associated with synthetic vasopressin and vasopressin immunoreactivity
from pituitary glands. This was not seen in the experiments with foetal muscle
extract. The occurrence of apparent vasopressin immunoreactivity in foetal muscle
extracts in both gel filtrated 1M acetic acid extracts and C8-silica cartridge eluates is
presumably therefore due to non-specific interference by other higher molecular
weight proteins that are retained on the adsorbent along with the peptides being
studied.
The levels of this interference are not significantly related to growth as shown
by Figure 5.3, and so cannot be said to be a feature specific to development. The
interference may be a reflection of tissue damage or bruising produced through the
process of termination, as it seems the most likely interfering protein is haemoglobin.
Homogenates and supernatant are brown in colour, and some of this colour is
retained on the column when muscle extract is passed through the column. Upon
elution of the retained fraction, when the eluate is dried under vacuum, a brown
pellet is formed. The addition of assay buffer causes all of the extracted vasopressin
to be released into the buffer, but obviously some of the contaminating protein also
dissolves, causing the observed interference, although without any observable
discolouration of the sample. This is manifested as an inappropriately large estimated
concentration in the affected concentrated extract, which disappears with minimal
dilution.
Such interference was not seen in extracts of adult rabbit muscle, which was
not largely damaged in sampling, visibly contains less blood, and was observed to
produce a much smaller pellet than of foetal muscle when comparable weights of
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muscle were extracted. It is also apparent that this interference is not present when
extracting blood plasma or serum, when red blood cells are deliberately removed
prior to vasopressin extraction, or when lower weights of adrenal gland tissue are
extracted. But the observation of this background in the assay reveals an important
factor when describing limits of an assay. The calculated lowest detectable
concentration of the s278 assay is quoted as being 7.8pg/ml. However, this is an
artificial quality of the assay as concentrations lower than the background levels seen
in extracts muscle will not dilute normally. The minimal detection limit of the assay
is therefore higher when assaying biological samples, and it is a failing of these
studies on foetal muscle that this different limit was not found. The limitations of his
assay bring in to doubt the reported levels ofAVP in Figure 5.4.
The possibility that the high molecular weight interference is due to binding
of vasopressin by neurophysin cannot be wholly ruled out. However, the neutral pH
of the eluting buffer is not conducive to the stable binding of vasopressin to the
neurophysin (256). No assay for neurophysin was available to test this possibility.
Another possibility is that of the presence of a vasopressin degrading enzyme,
similar to that observed in extracts of testis (139). The enzyme broke down the tracer
and caused a lower radioactive count, which was interpreted as displacement of
binding. This seems unlikely for two reasons. First, the muscle was homogenised and
boiled in acetic acid, whereas the extraction of the rat took place on ice, perhaps
preserving activity that is lost (or simply not present) in higher temperature
extraction. Second, the retention of tritiated AVP in the high molecular weight
fraction of muscle samples suggests that immunoreactivity is physically retained,
whereas the immunoreactivity found in the rats testis at high molecular weight was
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found to be caused by to degradation of the tracer in sample tubes in the
radioimmunoassay.
Finally, the identity of a specific high molecular weight species capable of
binding vasopressin also could include a receptor to the peptide. This would be
consistent with the observations of a VI-type receptor in the L6 rat myoblast cell line
by Nervi et al (195), and would fit with a proposed model of the participation of
vasopressin (or vasopressin-like molecule that is recognised by the VI-type receptor)
in the maturation of skeletal muscle. Further study to attempt to demonstrate the
presence of the receptor was indicated.
The amounts of vasopressin shown in Figure 5.8 are values obtained by
pooling more than 20g of muscle, and are therefore the equivalent of no more than
2.5pg for every gram of muscle tissue extracted. This explains why it was impossible
to detect vasopressin immunoreactivity, either as a peak from Sephadex G-25
chromatography or in assays where non-specific interference was observed from
extractions of foetal muscle from mid-trimester foetuses. This is contrary to later
findings of Smith et al (187), but is in agreement with an earlier observation of Smith
that no significant amount of vasopressin (or oxytocin and vasotocin) could be
demonstrated in muscle sampled from 10 to 24 week old foetuses (257). Vasopressin
could not be demonstrated in either embryonic or foetal rat muscle by Adamo (258).
The proposed model of vasopressin action in foetal muscle requires the generation of
a local concentration of vasopressin as high as that required to exert an effect in
vitro. The lowest concentration that was observed to stimulate an increase in fusion
of L6 myoblasts was 1x10"9M, or in the range of lng/ml (194, 195). For 2.5 pg/g of
vasopressin to create a concentration of lng/ml within a g of tissue would need the
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vasopressin to be contained within 2.5pi of interstitial fluid which, assuming the
density of foetal muscle is similar to adrenal tissue, is the equivalent of 0.25% of the
total volume of a gram of muscle. Nussdorfer quotes a figure of 2-3% for the
percentage volume of adrenal tissue (180), and although adult skeletal muscle is
densely packed and may conceivably have a density approaching that, foetal muscle
is comprised ofmany much smaller unfused cells with a far lower density. Thus, the
conclusion drawn from the results described above is that a significant amount of
vasopressin could not be identified any foetal muscle sampled.
5.3.3 Foetal adrenal glands
It was also possible to demonstrate low amounts of vasopressin in foetal
human adrenal glands. This immunoreactivity displaced tracer binding over a range
of dilutions in the RIA for vasopressin in parallel with the synthetic peptide, and
when present in sufficiently high levels was shown to elute at the same volume as
vasopressin from a pituitary gland when subjected to gel filtration (Figure 5.7). The
relationship found between the development of the foetus and the amount of
vasopressin immunoreactivity in the adrenal gland extract is one that is considered to
merit further investigation. Levels found in those glands from smaller foetuses are
low, and though it is conceivable that these levels are due to the same contamination
as is seen in foetal muscle, the concentration of the immunoreactivity and the
mobility of this immunoreactivity when concentrated C8-silica extract from pooled
adrenal glands subjected to G-25 chromatography suggests otherwise. It is
unfortunate that adrenal gland weights were not noted at the times of extraction, but
it seems obvious that the weight of the adrenal glands increases with gestation age
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and therefore body weight and foot length. Subsequent sampled adrenals were
weighed, and the range of weights of the glands were between 0.3g and 1.6g for
estimated gestation ages 14 weeks to 19 weeks. Taking these as a rough guide for
estimating the peptide content per gram of tissue (the estimated peptide contents
found in the extracted adrenals ranged from 8pg to 57pg), the data compare closely
with one of the two reports of vasopressin concentration in the foetal human adrenal
gland. Nicholson and co-workers reported a level of 80pg/g from adrenal tissue
pooled from five foetuses of differing gestation ages (138). Neither the ages nor the
weight of the adrenal glands that produced this figure are stated. It should be noted
that the vasopressin per gram of tissue ratio is lower in larger adrenal gland samples.
Ravid and co-workers detected immunoreactivity in the adrenal glands of 9
foetal or neonatal samples from foetuses ranging from 28 to 40 weeks gestation, and
levels were close to those described here (ranging from 2.8 to 59pg/gland) (164).
However, some of the foetuses were anencephalic, and the time of delay between
death and freezing prior to extraction ranged from 5 to more than 48 hours, and given
these factors it is difficult to assess the usefulness of the information provided by this
study. They also show extremely low amounts of immunoreactivity gained from rat
foetal adrenal glands. The reason for this could be the low yield from the Vycor glass
powder extraction, but the extraction efficiency for this method has been shown to be
better than 80% (259). The foetal rat adrenal glands that were extracted were
extremely small (less than lmg), and so it is not unexpected that low amounts are
detected.
mRNA for vasopressin has been detected in adult rat adrenal tissue (260).
Along with the observations ofNicholson and co-workers that the neurophysin could
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also be found in foetal human adrenal glands (138), the results shown in Figure 5.4
suggest a developmental aspect of the ontogeny of adrenal gland associated
vasopressin. However, the conclusions drawn from the study of C8-silica extracted
muscle was that extraction with C8-silica sometimes produced samples that
demonstrated a high background, and although further studies were carried out to
confirm the nature of the immunoreactivity from pooled samples, the veracity of the
presented relationship between foetus age and levels of vasopressin in the adrenal
remains to be definitively described. The use of molecular weight filters after solid
phase extraction would be essential in further work to elucidate this relationship.
Nonetheless, significant concentrations of AVP were observed in foetal
adrenal glands. Whether this AVP has a role in the development of the foetal adrenal
gland or some aspect of physiological control in the foetus remains to be seen, and




Immunochemical Analysis of Extrahypothalamic AVP and
the Vla-Vasopressin Receptor
6.1 Introduction
The results of experiments described in Chapter 5 hint at the presence of a
vasopressin binding factor in extracts of foetal skeletal muscle. Vasopressin
immunoreactivity was retained in high molecular weight fractions when extracts of
tissues were subjected to Sephadex G-25 gel filtration, suggesting the binding,
specific or otherwise, of vasopressin.
The presence of a receptor on the myoblast cell is a requirement of any model
describing a role for vasopressin in the development ofmature muscle, as a means of
transduction of the vasopressin signal to initiate fusion. In the rat L6 myoblast cell
line, functional vasopressin receptors have been identified, and characterised as the
Via subtype (191, 194). Demonstration of presence of the vasopressin receptor, and
localisation of the receptor at a cellular level in a developing muscle would be
important.
6.1.1 Immunoblotting
It was decided to use an established method to first try to demonstrate the
presence of the vasopressin receptor in foetal skeletal muscle tissue.
Gel electrophoresis of proteins is a powerful technique, because it allows the
separation and resolution of the protein components of a sample. Analysis of proteins
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by staining using substrates such as Coomassie dyes allows the examination of the
overall pattern of proteins within a sample, but specific identification of a protein
requires immunochemical detection, and gels used in electrophoresis are too fragile
to tolerate the procedure.
Blotting - the transfer of separated proteins onto a membrane - immobilises
these proteins and makes them more accessible to sensitive methods of detection that
allow identification. The technique originated from capillary blotting of DNA as
described by Southern (261). Towbin used electroelution to transfer proteins from
gel to membrane (262), but it was Burnette who first coined the term "Western
blotting" in describing the transfer of proteins from an SDS-polyacrylamide gel to a
nitrocellulose membrane with the subsequent antibody based detection of a protein
on the membrane (263). The technique has developed to the point now where it is a
highly effective way to use antibodies to detect the presence, molecular weight, and
relative abundance of proteins from samples. The technique has been further
enhanced with the advent of chemiluminescence (the emission of light from a
chemical reaction), a non-hazardous alternative to radiography that requires no
special facilities or disposal, and is flexible in terms of adjustment of conditions and
exposure to film to generate images. It also allows the investigator the opportunity to
re-examine the same blot with different antibodies to profile a sample.
Few reports exist of the use of Western blotting to characterise the Via
receptor. This is undoubtedly due to the low level of expression of the receptor even
in tissues where it is shown to exert an effect (41). The Via receptor is usually
characterised in other ways, such as radio-ligand binding studies or the use of non-
peptide ligands (56). Park and colleagues demonstrate the presence of the Via
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receptor in the renal medulla using a variety of techniques including Western
blotting, and characterise the receptor as a 44.2kDa protein (58).
Use of the antibody vivian has been reported in positive Western blot analysis
of cultured cells (221), and this antibody was used to attempt to identify the receptor
in foetal extracts.
6.1.2 Immunohistochemistrv
Immunoreactivity with a vasopressin antibody was observed in samples of
extracts of foetal human adrenal gland (Chapter 5). Results describing
immunoreactivity in the rat adrenal medulla would confirm the effectiveness of the
technique, as this has been previously reported (164, 166), and localisation of the
vasopressin in foetal adrenal tissues would give an indication as to the role, if any, of
vasopressin in the developing foetal adrenal gland. The extraction of vasopressin
from skeletal muscle could be further tested by the use of an alternative antibody
raised against a vasopressin antigen. It was decided to utilise immunohistochemistry
to attempt to localise vasopressin and vasopressin receptor immunoreactivity.
Immunohistochemistry uses an antibody to link a cellular antigen specifically
to a stain, implying that any specific staining at a location is due to the presence of
that antigen. Tissues sections can be prepared either from frozen samples, where the
tissue is mounted at low temperature (usually after snap freezing) and sections are
cut in a cryostat (essentially a refrigerated microtome), or from paraffin wax
embedded blocks where the tissues has been fixed, usually by an aldehyde based or
an alcohol based fixative. Frozen sections have an advantage in that they display
good preservation of antigen immunoreactivity, but do not allow fine resolution of
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morphological detail. Fixation by its nature involves formation of chemically stable
links to stabilise the morphology of the tissue, and loss of antigen immunoreactivity
is a common effect most fixation methods. However, antigens can be 'retrieved' by
the breaking of these crosslinks, and significant loss of immunoreactivity can be
minimised after appropriate treatment.
For the purpose of localisation of vasopressin and the associated Via subtype
receptor, it was decided to use sections prepared from samples that had been fixed in
formalin, processed, and embedded in paraffin wax. Use of paraffin wax embedded
sections also has the advantage that readily available archive material can be
accessed once a method has been established, allowing greater numbers of samples
to be processed.
6.2 Results
6.2.1 Analysis ofWestern blots
Two extraction methods were used identify the vasopressin, and two methods
were used to try to elucidate the relative levels of expression at different stages of
gestation.
Samples extracted using TRIzol reagent demonstrated that the vasopressin
receptor could be positively identified in samples from 15 weeks gestation and older
(Figure 6.1 A), and that the molecular weight of the positive signal was consistent
with both an internal control (Figure 6.1A lane 3) and published reports (58, 221).
Via was also identified in a foetal liver sample, although signal was only seen at the
higher molecular weight associated with Via. In the blot shown, signal emanating
from the higher molecular weight region was blocked, presumably by the high
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amount of protein transferred at that molecular weight from a gel already overloaded
with protein in order to generate an image. Subsequently it was realised that the
levels of protein, although ostensibly similar, showed variation in their composition.
Levels of haemoglobin in the homogenate, while undoubtedly the major component
of protein, varied markedly between samples, and so normalising using protein
concentration involved inherent errors.
In an attempt to gain information about the developmental expression of the
vasopressin receptor, the amount of protein in lysis buffer extracted samples added to
a lane was altered with reference to a positive control for the development of skeletal
muscle, dystroglycan B - dystroglycan (224). Positive signal for this muscle specific
marker was seen in all foetal muscle samples (Figure 6.1). No signal was seen in the
positive control sample, human liver.
Positive signal was seen in muscle samples of older foetuses, but it was not
possible to gain definitive identification of the receptor at any age. Figure 6.2 shows
a blot which typifies this. The positive control sample (lane 1) gave a single band at
approximately 43kDa. This is in agreement with data shown by Park et al, which
show a positive band at approximately 44.2kDa (58). However, muscle samples gave
multiple strong bands, with only a weak band at the expected molecular weight.
(Whilst negative control experiments where vivian was replaced with normal rabbit
serum did not show a similar pattern at the predicted molecular weight of the VI a-
vasopressin receptor, signal was seen at higher molecular weights (data not shown).)
This is in agreement with a pattern reported by North et al (221). North explains the
pattern of banding gained with vivian by citing reports that the receptor weight is
much higher with glycosylation of the protein (57). The interpretation of the blot
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shown in Figure 6.2 is that a positive identification of the Via receptor has been
made in at least the sample of muscle from the 18 week foetus. However, it was not
possible to make a quantitative statement about the relative abundance of B-
dystroglycan and Via receptor in the samples.
6.2.3 Immunohistochemical analysis
6.2.3.1 Brain tissue
Control tissue stained positively for vasopressin, in keeping with the
observation that the hypothalamus is the major site of vasopressin synthesis, and the
posterior pituitary gland is the major site of storage and release of vasopressin.
Absence of staining with the negative control serum (Figure 6.3A), which was
generally observed in all negative control slides, is replaced by a strong specific stain
when slides were incubated with gonzo (Figure 6.3B). High magnification reveals
the staining to be entirely cytoplasmic and entirely within structures identifiable as
neuronal in nature (Figure 6.3C). Also shown is the positive staining seen in the
posterior pituitary glands from a foetus of 14 weeks estimated gestation age (Figure
6.3D).
6.2.3.2 Muscle tissue
Hemotoxylin and eosin stained slides confirmed that muscle was maturing
over the middle trimester. Muscle taken from early foetuses generally showed much
less differentiation of the myoblasts, which were more numerous. Myoblasts are
distinct from mature muscle cells by their mononuclear nature. The nucleus is
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usually centrally positioned. This can be seen in Figure 6.4A. The muscle from a 14
weeks foetus is distinctly unlike mature skeletal muscle. Muscle cells in an 18 week
old foetus are generally much more dense and nuclei are peripherally positioned on
those cells that have fused and are entering a phase of growth and further fusion
(Figure 6.4B). However, there are still myoblasts present in the tissue. These
observations are qualitative in nature, and no attempt was made to standardise the
appearance of a typical sample and correlate this with weight or foot length.
Positive staining was seen with the use of a commercial antibody to vimentin
(Figure 6.5) The strong staining seen in younger samples was reduced with older
samples, but this is again a qualitative judgement. This is in agreement with
observations by Sarnat and co-workers, that foetal skeletal muscle expresses
vimentin at all gestation ages (225) and demonstrates that that the tissue was
properly fixed and antigen retrieval was properly performed. Absence of, or weak
staining is therefore due to a lack of the antigen in the tissue examined rather than the
antigen being inaccessible to the antibody.
It was not possible to achieve positive staining with either the antibody to
AVP or the vasopressin Via receptor. Increasing the concentration of the antibody
only increased the background without any appreciable specific staining. Staining
gained with Vivian was light, and not obviously different from the background
staining associated with gonzo.
6.2.3.3 Adrenal glands
Foetal human adrenal glands also showed a progression of development
associated with increased gestation age in the samples that were stained with
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haemotoxylin and eosin. The permanent cortex lining the gland generally was seen to
thicken as gestation age increased. No significant staining could be found in foetal
adrenal medulla cells of any of the samples examined, although it was never sought
to identify foetal medulla cells.
The phenomenon of the incursion of medullary tissue into adrenal cortex in
rat adrenal glands is shown in Figure 6.7. The classical scenario of the distinct layers
of the gland shown in Figure 6.7A is in contrast to the often seen more intimate
situation. The higher power photographs clearly show the difference between the cell
types of the island medullary cells and the surrounding cortex cells. Positive staining
was repeatedly observed in rat adrenal medulla tissue. Examples of the medullary
rays and islands of chromaffin cells in the cortex, that were described by Gallo-Payet
and colleagues (181), are shown in Figures 6.8B and C. Significant staining was
observed in the rat medulla, confirming previously published observations (166).
Staining was most intense in cells that were intercalated within the cortex tissue - this
was observed regardless of the location of the cells within the cortex.
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A: Blot probed with vivian antibody




B: Blot probed with anti-B-dystroglyan antibody
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FIGURE 6.1 Normalisation of foetal muscle samples for the Western analysis
of vasopressin receptor
A Protein samples of foetal muscle were normalised by absorbance at 280nm
and equal amounts of reduced protein were loaded into each lane. Shown is a blot
where sufficient volume was added to generate positive signal in some of these





3: MCF-7 cell extract
4: 18 week old foetus
5:16 week old foetus
6: 13 week old foetus
7: 15week old foetus
B Extracts produced by homogenisation in lysis buffer of samples of foetal
muscle of various gestation ages were assayed for protein content. 25pg of reduced
protein was loaded in each lane and separated by SDS-PAGE using a 12%
polyacrylamide gel. The separated proteins were transferred to a membrane and
incubated with an anti-B-dystroglycan antibody overnight at 4°C. Developed blots
were used to adjust the amount of protein added to give a qualitative rising
concentration of positive signal, in an attempt to establish the relative changes in
expression of B-dystroglycan and the vasopressin V1 a receptor.
The relevant portion of a developed blot is shown along with the position of the
migration of the closest molecular weight marker.
Samples
1: Human liver positive control
2:12 week old foetus
3:15 week old foetus
4: 16 week old foetus
5:18 week old foetus
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FIGURE 6.2 Western analysis of foetal muscle extracts
Extracts from samples of foetal muscle, normalised for increasing concentrations of
beta-dystroglycan (described in Figure 6.1), were reduced and separated by SDS-PAGE
using a 12% polyacrylamide gel. The separated proteins were transferred to a membrane
and incubated with vivian antibody overnight at 4°C. The relevant portion of the
developed blot is shown along with the position of the migration of the closest molecular
weight marker.
1: Human liver positive control
2: 18 week old foetus
3:15 week old foetus










FIGURE 6.3 Positive staining of tissues known to express AVP
A Staining was absent when the section is incubated with the negative control
serum. This which was generally observed in all negative control slides.
Magnification x40
B Shows a low power view of the positive staining in magnocellular neurones
of the hypothalamus. The section was incubated with gonzo diluted to 1/400.
Magnification x40
C A single magnocellular neurone is shown at high power. Staining is confined
to the cytoplasm, and the nucleolus is clearly visible at the centre of the nucleus. The
section was incubated with gonzo diluted to 1/400.
Magnification x200
D The strong positive staining seen in the posterior pituitary glands from a fetus
of 14 weeks estimated gestation age. The section was incubated with gonzo diluted to
1/400.
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FIGURE 6.4 Morphological changes in developing foetal skeletal muscle
(legend overleaf)
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FIGURE 6.4 Morphological changes in developing foetal skeletal muscle
The figures demonstrate the qualitative changes that happen in the development of
muscle in as short a period as a month.
Sections of muscle were stained with hemotoxylin and eosin.
A Muscle tissue from a 14 week old foetus is distinctly unlike mature skeletal
muscle. The majority of the muscle cells in the tissues were myoblast cells.
Magnification x20
B Myoblasts are distinct from mature muscle cells by their mononuclear nature.
The nucleus is centrally positioned in these cells. Many of the cells in this section
have lost their nucleus, leading to the pink halo structure seen here.
Magnification x200
C Muscle tissue taken from an 18 week old foetus is generally much more
dense. Fusion of cells leads to the formation of larger myofibrils. Nuclei are
peripherally positioned on those cells that have fused. The cells enter a phase of
growth and further fusion.
Magnification x20
D More typical morphology associated with skeletal muscle is seen in this
longitudinal section of skeletal muscle sample, from a foetus of 18 weeks gestation
Myoblasts have fused to form longer myofibrils, containing multiple peripheral
nuclei. Striations of the muscle tissue is sometimes seen. There are, however, still
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FIGURE 6.5 Positive staining for a marker ofmuscle development
(legend over leaf)
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FIGURE 6.5 Positive staining for a marker of muscle development
The effectiveness of the antigen retrieval process was demonstrated using a
commercial antibody to vimentin. Slides were counterstained with hemotoxylin.
A Positive staining is seen in the myoblast cells of a section from a 14 week old
foetus. The staining is non nuclear, in keeping with the description of vimentin as an
cytoplasmic intermediate filament.
Magnification x40
B Positive staining is much less dense on a section of tissue which is more





FIGURE 6.6 Development ofmedulla of adrenal gland
(legend overleaf)
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FIGURE 6.6 Development ofmedulla of adrenal gland
A The majority of the cells in the foetal adrenal gland are large eosinophilic
cells, referred to as the foetal zone. The other cells seen are permanent cortex cells,
seen on the edge of the tissue and at the centre. The cells are basophilic, and have
tightly packed nuclei. The gland is arranged in tubes with permanent cortex lying
over the foetal zone cells. The foetal adrenal lacks a definitive medulla. Chromaffin
cells are present but scattered throughout the cells and difficult to identify in
hemotoxylin and eosin sections.
Magnification x20
B At birth, the foetal adrenal gland reduces in size rapidly, the permanent
cortex cells undergo growth and maturation to form the familiar three layered
structure of the cortex, and with the disappearance of the foetal cells the chromaffin
cells aggregate to form the central medulla.
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FIGURE 6.7 Rays and islands of medullary tissue in rat adrenal cortex
(legend overleaf)
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FIGURE 6.7 Rays and islands of medullary tissue in rat adrenal cortex
The commonly held conception that the medulla and the cortex of the adrenal gland
are discrete entities with minimal interaction (Figure 6.7A, Magnification x20) is
shown to be false in sections of rat adrenal glands stained with hemotoxylin and
eosin.
B A ray of blue basophilic medulla cells intrudes into the surrounding cortex,
whilst another set of cells are completely surrounded by cortex cells.
Magnification x20
C,D Higher magnification of these two sets of cells definitively shows the






FIGURE 6.8 Positive staining for AVP in rat adrenal glands
(legend overleaf)
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FIGURE 6.8 Positive staining for AVP in rat adrenal glands
A Low power view of section of adult rat tissue stained positively or
vasopressin using gonzo (1/100 dilution). Both a ray ofmedulla tissue and an island
are seen, both with markedly stronger staining than that seen in chromaffin cells
more centrally positioned in the medulla.
Magnification x20
B Higher power view of the island ofmedullary tissue shown in A. The staining
is seen to be cytoplasmic and not seen in the nucleus or in surrounding cells of the
cortex, indicating it is specific and genuine immunoreactivity.
C Low power view of section of adult rat tissue stained positively or
vasopressin using gonzo (1/100 dilution). Islands of positively staining medulla cells





Attempts to define a developmental aspect to the expression of the
vasopressin receptor in foetal skeletal muscle were not successful. Younger foetuses
did give a positive signal for the V1 a receptor, but it was not possible to translate
immunoreactivity into a relative abundance of the receptor at different
developmental stages, due to the low number of samples and the inherent problems
associated with Western analysis of the Via receptor. The samples used for the
initial phase of study were TRIzol extracted and gave rise to a much cleaner sample
than those gained from lysis buffer extraction. This is reflected in the variation in the
background seen in the two blots probed using the same antiserum preparation
(Figure 6.1A and 6.2).
The appearance of the double band of immunoreactivity at the higher
molecular weight in Figure 6.1A is consistent with the dimerisation of the receptor,
together with differences in the amount of glycosylation of the receptors. No reports
of the occurrence or importance of dimerisation of the Via receptor could be found.
Dimerisation of the V2 receptor has been observed, but the interpreted significance
of this varies. Sadeghi considers the phenomenon irrelevant to function (or at least
not necessary for function) (264), whereas Zhu has demonstrated that truncated V2
receptor will inhibit the function of wild type receptors by forming dimers (265).
This is complemented by the work of Herbert, who generated SDS-resistant dimers
of beta2-adrenergic receptors, and used a peptide portion of the receptor to inhibit the
activation of whole receptor molecules (266). The cause of the dimerisation in the
samples shown here is not known.
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At the molecular weight associated with the single receptor a double band
also appears, and whilst this could be explained by the differential glycosylation of
the receptor, it would seem more logical to see a smearing of the signal in at both the
monomer and dimer level. Deglycosylation of a sample and subsequent Western
analysis (similar to studies described by Wheatley et al (37)) to detect a shift in the
molecular weight of the vasopressin receptor would clarify this.
The presence of the receptor later in gestation rather than earlier would
suggest that the receptor appears with increasing maturity of the muscle, rather than
any correlation with ability to undergo fusion. The developmental expression of the
Via receptor in liver and kidney tissue has been demonstrated previously (64, 65),
but more work is required to define any such situation in foetal muscle.
6.3.2 Immunohistochemistrv
Experiments described in this chapter were carried out in order to localise
previously described immunoreactivity or the potential for it. Vasopressin had been
identified in foetal human adrenal glands and in adult rat adrenal glands through
radioimmunoassay. Via subtype receptors were tentatively demonstrated in a
Western blot using extracts of foetal skeletal muscle. Staining was only successfully
seen in rat adrenal glands.
The finding that medullary rays stain positively for vasopressin provides an
explanation for the observations that cortex tissues contain vasopressin (bovine in
particular) (165). When the cortex and medulla are separated by dissection, some
medulla is retained within the cortex, giving a positive result when extracted and
assayed for vasopressin. These observations also give support to the belief that
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vasopressin acts as a paracrine regulator of adrenal cortical function (172). In the
absence of a circulatory mechanism to distribute the peptide, and given the relatively
low amounts of vasopressin in the adrenal gland itself, it seems logical that the
peptide should be distributed in areas where is will be able to exert most effect. This
observation may be an artefact of the manner of death of the rats these samples were
taken from; there can be few more systematically stressful stimuli than stunning and
decapitation, and so the staining may actually reflect the remaining vasopressin that
has not been secreted in response to this. Further work is required to clarify this, and
will need to involve more sensitive techniques.
Studies to locate receptor immunoreactivity and peptide reactivity in foetal
tissue was hampered by the lack of sensitivity of the techniques used.
Immunohistochemistry supplied indeterminate results at best, and options to optimise
the staining were limited. Western blotting will provide the best method to confirm
the developmental appearance of the receptor in muscle tissue. Further attempts to
localise the receptor will rely on techniques such as in situ hybridisation, as the




Discussion and Recommendations for Further Study
7.1 Summary
The experiments described in this thesis were carried out with the aim of
supplying more information about the synthesis of extrahypothalamic vasopressin,
and the possible role of vasopressin in the development of skeletal muscle in the
foetus. It had been suggested that high concentrations of vasopressin were present in
the muscle of human foetuses from approximately 15 weeks to term, with a lowering
of the levels correlated with an increase in gestation age. Other studies showed that
vasopressin promoted the fusion of cultured cells that retained the myoblast
phenotype, and taken together these studies suggest a role for vasopressin in the
formation of multinucleated muscle fibres required for the formation of normal
muscle.
The occurrence of extrahypothalamic vasopressin is an established fact.
Similar studies in the adrenal gland have established a model for the progression of
knowledge, from studies based on the immunological profiling of a tissue - the
detection of vasopressin and the neurophysin, and associated receptors, to the use of
molecular biological techniques to confirm the presence of transcripts of genes for
vasopressin and both the Via and Vlb receptor subtypes. It was proposed to carry
out an investigation of vasopressin in foetal muscle with a similar pattern. By use of
a sensitive and specific radioimmunoassay for vasopressin it was hoped to show that
there was a relationship between the amount of vasopressin in the muscle, and the
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required amount of myoblast fusion to give rise to sufficient mature multinucleated
myofibrils to enter into the growth phase of development at the particular gestation
age of the foetus. It was also hoped to localise the immunoreactivity in terms of a
cell type or a structure within the developing muscle. As the foetus grows in size, it
is assumed that the number of myoblasts diminishes, and so there would be a
reduced requirement for high levels of vasopressin.
7.1.1 Initial observations
The use of sheep and rabbit antibodies in the radioimmunoassay for
vasopressin was validated. A serum pool to be used as a source of antibody to
vasopressin was characterised (s278 antiserum). It was shown that the antibody was
specific and sensitive to vasopressin when compared to other related peptides. A
standard curve was established for the s278 antiserum. When compared with the
already characterised assay using a rabbit polyclonal antiserum (tgl), the two
antisera provided similar extrapolated concentrations of the same sample of synthetic
vasopressin in their respective assays.
The assay of extracts of foetal muscle in acetic acid was attempted. Results
from the two assays were not similar, and when the samples were diluted did not
provide consistent data. Acid was shown to have an interfering effect on the
estimation of vasopressin, and the amount ofmuscle extracted per unit volume of 1M
acetic acid used to homogenise the muscle was show to have a direct effect on the
concentrations of vasopressin estimated to be in the sample.
It was concluded that it was not possible to easily assay the extract of foetal
muscle in 1M acetic acid and arrive at a reliable estimate of the amount of
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vasopressin within a sample. An extraction step to remove acid interference was
indicated.
7.1.2 Solid phase extraction of vasopressin from tissues
Octyl-silica (C8 silica) cartridges were used to attempt to identify specific
vasopressin immunoreactivity in acid extracts of foetal muscle. The use of C8 silica
cartridges was validated by the demonstration that synthetic vasopressin could be
reliably extracted from 1M acetic acid with a high recovery, and that extracting
vasopressin from extracts ofmuscle provided a reduced recovery that was judged to
be sufficient to justify the use of this method. Positive control samples were
extracted in the same way, and levels of vasopressin were similar to published
values.
A previously undescribed relationship between the development of the foetus
and the amount of vasopressin in the developing adrenal gland was also tentatively
observed.
Immunoreactivity apparent in foetal muscle, adrenal glands and pituitary
glands was subjected to Sephadex G-25 gel filtration with subsequent
radioimmunoassay. Adrenal gland and pituitary gland immunoreactivity was
observed to be of a similar mobility to synthetic vasopressin. Immunoreactivity
associated with extracts of foetal muscle was observed to elute consistent with it
possessing a heavier molecular weight. When large amounts of muscle were
extracted and added to the column, small amounts of immunoreactivity were
isolated, but these were not sufficient to generate concentrations of vasopressin
required to cause fusion of myoblast cells in culture.
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It was concluded that the source of vasopressin-like bioactivity which may be
responsible for a similar action as that seen in culture could not be isolated from
foetal muscle using the C8-silica cartridge method, and therefore the source was
unlikely to be vasopressin itself.
7.1.3 Demonstration of vasopressin receptor in foetal skeletal muscle extracts
Vasopressin immunoreactivity was seen to be retained in high molecular
weight fractions when extracts of all tissues were subjected to Sephadex G-25 gel
filtration. As well as this observation, the proposed model for the involvement of
vasopressin (or now, a vasopressin like molecule) required the presence of a
vasopressin receptor in foetal muscle cells. Western blotting was carried out using a
specific antibody to the human vasopressin Via subtype receptor in an attempt to
demonstrate the presence of such a receptor.
Positive signals could only be identified in older samples. Positive results
could not be obtained from other samples from lower gestation foetuses. However,
the number of samples examined using this technique was low, and as such can only
be regarded as preliminary data.
7.1.4 Immunohistochemical analysis
Immunohistochemistry was used to confirm the observations made in
Chapters 3 and 4 of vasopressin immunoreactivity in extracts from human foetal
adrenal and adult rat adrenal, and the observations of vasopressin receptor
immunoreactivity in extracts of human foetal muscle.
170
No significant staining was observed in foetal adrenal gland sections.
Significant vasopressin staining was seen in the chromaffin cells of the medulla in
the adult rat, and this was believed to be the first description of the appearance of
vasopressin staining chromaffin cells in the cortex of the adrenal gland.
Results with the vasopressin receptor antibody were inconclusive, even
though it was established that the antigens were available in the tissue.
7.2 Discussion
The failure to demonstrate high levels of vasopressin in foetal muscle posed a
problem in the investigation of vasopressin as a factor in the differentiation of
vasopressin. No experiments described here demonstrated the high concentrations of
vasopressin in foetal skeletal muscle described by others (187). As far as was
possible, it was attempted to recreate exactly the experimental conditions described
by Smith et al, since no other reports of similar findings were apparent. Despite this,
no evidence of significant amount of vasopressin immunoreactivity, and therefore
vasopressin, could be found in any extract of human foetal muscle.
Experimental conditions and the delay before sampling could explain this,
and so the experiments do not rule out the possibility that vasopressin genuinely is
present is high concentrations in foetal muscle. No data is available on the half life of
vasopressin in the foetus, and it could be that it has been broken down in the time
before the sample can be frozen.
Taken alone, this should not detract from the theory that vasopressin-like
activity is involved in the development of skeletal muscle in the foetus. In this
respect, the experiments described have merely shown that the active principle
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responsible for the action observed in rat myoblast cell culture, and mimicked by
vasopressin, was not immunoreactive to the antibodies used in these experiments. A
candidate for this is the vasopressin like peptide described by Hanley, that was
isolated from the rat sympathetic nervous system (120). It may be that this substance
is the true source of the bioactivity, and further work could be carried out to further
characterise the vasopressin like peptide. In particular, the bioactivity of the peptide
with reference to the Via receptor subtype should be established.
Another alternative could be that vasopressin is not required in the
concentrations seen in vitro to exert this effect in vivo. The division of tissues into
those that produce vasopressin and use the peptide as an autocrine or paracrine
hormone and those that are under the control of circulating vasopressin is still valid.
As has been stated, the expression of the Via receptor seems to be under strict
control and can be expressed at different developmental stages. Data defining the
lack of a receptor at earlier gestation ages were unconvincing. The presence of the
receptor in the tissue, therefore, is not a coincidence, and it may be that the
designation of vasopressin as a maturation factor in muscle development is correct,
but the model of it being expressed by the same tissue is not. The example given
earlier of activation in platelet cells is pertinent. Whilst it was initially observed that
high doses of AVP were required to activate platelets, Wun and colleagues
demonstrated activation of platelets after incubation with physiological
concentrations of AVP (95). The overt effects seen in in vitro experiments may not
reflect the actual required concentration, which could be supplied by circulating
levels, and the model proposed for the role of vasopressin in developing skeletal
muscle merely requires that its designation as an extrahypothalamic producer of
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vasopressin be changed to that of being under the influence of circulating
vasopressin.
However, reservations about the veracity of the observations in the rat L6 line
exist. It has been pointed out that in normal physiological function, the receptor is
not expressed unless is it required as a target for the hormone itself to perform a
function. The presence of the hormone is as important a requirement as the
expression of the receptor. Whilst the L6 cell line may be a good tool for the study of
the physical mechanism of muscle cell fusion, the fact that the cells spontaneously
fuse in culture raise questions about the usefulness and accuracy of extrapolating
data obtained with these cells to the situation in the whole animal (193). Expression
of the vasopressin Via receptor is a feature of many cancer cells, and it is thought
that vasopressin may be a growth factor for certain types of cancer (221). L6 cells are
immortalised muscle cells that were treated with a tumour promoter in order to
encourage proliferation (192).
Perversely, the very mechanisms that make it conceivable that vasopressin is
involved in the process of fusion, are also implicated in the reasoning to suggest that
the effects of vasopressin are an artefact. The expression of the vasopressin receptor
on the immortalised cells may be a function of the immortalisation process itself.
Thus, the worry is that
"...neuropeptides and growth factors use the same intracellular second messengers
and that the physiological response of the target cell under certain circumstances is
more dependent on the phenotypic expression of the target cell than of the stimuli to
which it is exposed" (267).
In addition, experiments where primary satellite cells are used do not seem to
justify the case for, or against, vasopressin involvement. Satellite cells are of a
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distinct type, and their responses are different to embryonic myoblasts in many ways.
Similarity of the response to vasopressin by L6 cells and satellite cells from primary
culture may indicate a lack of similarity to embryonic myoblasts.
7.3 Recommendations for further study
The areas of extrahypothalamic expression of AVP and development of
skeletal muscle are fascinating, and the exploration of single aspects of either
provides views of many more that could be equally productive. The experiments
described here represent an initial investigation into some examples of this, and point
the way to further research that could be done.
Whilst it may be a point of some contention, the use of foetal human samples
to study development of tissues should be continued. Controls are present within the
system of recruitment to ensure that the patient is not coerced or pressured into
donating or going through with the procedure. For investigators willing to participate
in this type of research, it is a valuable source of material.
Experiments carried out to demonstrate and describe the presence of the V1 a
receptor were confounded by a lack of sensitivity. The first thing to be established is
to confirm the tentative observation that vasopressin receptor is only expressed later
in gestation. This can be done in a variety of ways. Receptor binding studies are
commonly used to characterise receptors, and the isolated membrane could be used
to determine the binding seen in foetal muscle. Future research would benefit
immensely from harnessing the power of molecular biological techniques. The
presence or otherwise of the Via receptor could quite easily be determined by RT-
PCR.
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The observation that an increasing vasopressin content was found in foetal
adrenal glands is an interesting one. However, this observation was only tentatively
stated due to the problems experienced with the sensitivity of the assay used to
measured the immunoreactivity, and further work to describe better the content of
foetal adrenal glands is necessary. Again, RT-PCR would be a straightforward way
to examine expression of the vasopressin gene in the foetal adrenal.
The most successful aspect of this work has been the discovery of the
staining of medullary rays for vasopressin in rat adrenal glands. The staining was
strongest on the outside of the medulla, and work should be carried out to determine
if this was an artefact of the sampling process. In this respect the research would be
the same as should be carried out to further elucidate the role vasopressin may play
in the development of muscle in the foetus. Similarly, in situ hybridisation would
supply information in the rat adrenal gland as to the distribution of the vasopressin
mRNA in the medulla. If expression is even throughout the medulla, then the theory
that vasopressin is distributed where it is most effective would have to be re¬
evaluated. It would also be interesting to study the distribution of the receptor type in
the medulla to see if they have a bias of expression between the inner medulla and
the medullary cortical junction.
Finally, a valuable tool in the study of the expression of AVP in the adrenal
gland could be the Brattleboro rat. This rat has a base pair deletion in the vasopressin
gene and so does not express AVP in the hypothalamus (162). However, AVP
immunoreactivity has been demonstrated in the Brattleboro rat testes (268), ovary
(122), adrenal gland (161), thymus (149), and in other parts of the brain (163).
Different mechanisms of the expression and the quality control processes involved in
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translation in these tissues could easily and successfully be studied using these
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